{"content":"<li class=\"n-box-item date-title\" data-end=\"1546923599\" data-start=\"1546837200\" data-txt=\"Monday, December 23, 2019\">Monday, January  7, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3421253\" data-ts=\"1546900505\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DPLO\" target=\"_blank\">DPLO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421253-unp-ne-cpe-among-notable-after-hour-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UNP, NE &amp; CPE among notable after hour movers</a></h4><ul><li><strong>Gainers: </strong><a href='https://seekingalpha.com/symbol/DPLO' title='Diplomat Pharmacy'>DPLO</a> <font color=\"green\">+11.7%</font>. <a href='https://seekingalpha.com/symbol/UNP' title='Union Pacific Corporation'>UNP</a> <font color=\"green\">+6.7%</font>. <a href='https://seekingalpha.com/symbol/CMC' title='Commercial Metals Company'>CMC</a> <font color=\"green\">+5.8%</font>. <a href='https://seekingalpha.com/symbol/MED' title='Medifast, Inc.'>MED</a> <font color=\"green\">+4.4%</font>. <a href='https://seekingalpha.com/symbol/CWEN' title='Clearway Energy, Inc.  Class C'>CWEN</a> <font color=\"green\">+4.2%</font>.</li><li><strong>Losers: </strong><a href='https://seekingalpha.com/symbol/NE' title='Noble Corporation plc'>NE</a> <font color=\"red\">-8.7%</font>. <a href='https://seekingalpha.com/symbol/GTT' title='GTT Communications, Inc.'>GTT</a> <font color=\"red\">-8.1%</font>. <a href='https://seekingalpha.com/symbol/HPR' title='HighPoint Resources Corporation'>HPR</a> <font color=\"red\">-7.9%</font>. <a href='https://seekingalpha.com/symbol/WLH' title='William Lyon Homes'>WLH</a> <font color=\"red\">-7.4%</font>. <a href='https://seekingalpha.com/symbol/CPE' title='Callon Petroleum Co.'>CPE</a> <font color=\"red\">-7.2%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3421253\" data-linked=\"UNP, NE &amp; CPE among notable after hour movers\" data-tweet=\"$DPLO $DPLO $UNP - UNP, NE &amp; CPE among notable after hour movers https://seekingalpha.com/news/3421253-unp-ne-cpe-among-notable-after-hour-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3421253-unp-ne-cpe-among-notable-after-hour-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421252\" data-ts=\"1546900242\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VIVO\" target=\"_blank\">VIVO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421252-meridian-bioscienceminus-1_7-on-preliminary-q1-revenues\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Meridian Bioscience -1.7% on preliminary Q1 revenues</a></h4><ul>   <li>Meridian Bioscience (NASDAQ:<a href='https://seekingalpha.com/symbol/VIVO' title='Meridian Bioscience Inc.'>VIVO</a>) has <font color=\"red\">dipped 1.7%</font> in postmarket trading after announcing <a href=\"https://seekingalpha.com/pr/17372810-meridian-bioscience-announces-preliminary-first-quarter-2019-revenue-first-quarter-2019\" target=\"_blank\">disappointing preliminary results</a> for first-quarter revenues.</li>    <li>The company sees revenues at $51M-$51.5M, compared with a year-ago $52.3M and consensus for $53.7M.</li>    <li>Revenues for Life Science are expected to be in line with the previous year, but the Diagnostics segment is weaker, Meridian notes.</li>    <li>\"Demand in the first quarter was softer than expected in both of our business segments,\" says CEO Jack Kenny. \"In Diagnostics, we experienced weakness in major molecular product lines. In Life Science, bulk order shipments, which are historically prone to quarterly swings, were also weaker than planned, particularly for immunoassay products and in China.\"</li>    <li>The company will hold its earnings call Jan. 24. It presents at the J.P. Morgan Healthcare Conference on Thursday at 1:30 p.m. ET.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3421252\" data-linked=\"Meridian Bioscience -1.7% on preliminary Q1 revenues\" data-tweet=\"$VIVO - Meridian Bioscience -1.7% on preliminary Q1 revenues https://seekingalpha.com/news/3421252-meridian-bioscienceminus-1_7-on-preliminary-q1-revenues?source=tweet\" data-url=\"https://seekingalpha.com/news/3421252-meridian-bioscienceminus-1_7-on-preliminary-q1-revenues\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:30 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421250\" data-ts=\"1546899755\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UNP\" target=\"_blank\">UNP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421250-union-pacificplus-6_7-after-bringing-vena-out-of-retirement-coo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Union Pacific +6.7% after bringing Vena out of retirement as COO</a></h4><ul>   <li>Union Pacific (NYSE:<a href='https://seekingalpha.com/symbol/UNP' title='Union Pacific Corporation'>UNP</a>) has <font color=\"green\">risen 6.7%</font> in postmarket trading on heavy volume after naming Jim Vena its <a href=\"https://seekingalpha.com/pr/17372629-union-pacific-names-jim-vena-chief-operating-officer\" target=\"_blank\">chief operating officer</a>, effective Jan. 14.</li>    <li>The 60-year-old Vena -- a former protege of Hunter Harrison at Canadian National (NYSEARCA:<a href='https://seekingalpha.com/symbol/CN' title='Deutsche X-trackers Harvest MSCI All China Equity ETF'>CN</a>) -- had retired in 2016 after 40 years with that railway.</li>    <li>At CN, he led the best operating ratio in North American rail and achieved the best safety incident ratio in company history.</li>    <li>He'll report to Union Pacific Chairman/President/CEO Lance Fritz.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3421250\" data-linked=\"Union Pacific +6.7% after bringing Vena out of retirement as COO\" data-tweet=\"$UNP $UNP $CN - Union Pacific +6.7% after bringing Vena out of retirement as COO https://seekingalpha.com/news/3421250-union-pacificplus-6_7-after-bringing-vena-out-of-retirement-coo?source=tweet\" data-url=\"https://seekingalpha.com/news/3421250-union-pacificplus-6_7-after-bringing-vena-out-of-retirement-coo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421236\" data-ts=\"1546897909\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STX\" target=\"_blank\">STX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421236-seagate-unveils-new-storage-solutions\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Seagate unveils new storage solutions</a></h4><ul><li>Seagate (NASDAQ:<a href='https://seekingalpha.com/symbol/STX' title='Seagate Technology'>STX</a>) <a href=\"https://seekingalpha.com/pr/17371192-seagate-levels-data-creation-ces-storage-solutions-fit-digital-life\" target=\"_blank\">announces</a> its newest lineup of storage solutions at <a href=\"https://seekingalpha.com/search/?q=CES19&amp;tab=news\" target=\"_blank\">#CES19</a>:</li><li>The LaCie line gains the Mobile Drive (max 5TB) and Mobile SSD with speeds of up to 540MB/s and max 2TB capacity. Both are available this month.</li><li>The Backup Plus family of portable external drives gets the Backup Plus Ultra Touch (1TB and 2TB capacities), Backup Plus Slim (1TB and 2TB), and Backup Plus Portable (4TB and 5TB). The Ultra Touch will become available next month and the others arrive in March. </li><li>For PC gamers, STX has the FireCuda 510 M.2 PCIe NVMe SSD with its ultra-small M.2 2280 form factor, 4K video processing, and high IOPS. There's also the BarraCuda 510 M.2 PCIe NVMe SSD for faster applications. The products will be available sometime this spring. </li><li>For enterprises, Seagate says the IronWolf 110 SATA SSD is the first purpose-built NAS SSD. IronWolf offers capacities of up to 3.84TB, includes Durawrite tech for faster read/write , and has up to 7000 TBW.  IronWolf 110 is available this month. </li><li>STX shares are <font color=\"green\">up 1.3%</font> aftermarket to $39.65.</li></ul><div class=\"tiny-share-widget\" data-id=\"3421236\" data-linked=\"Seagate unveils new storage solutions\" data-tweet=\"$STX - Seagate unveils new storage solutions https://seekingalpha.com/news/3421236-seagate-unveils-new-storage-solutions?source=tweet\" data-url=\"https://seekingalpha.com/news/3421236-seagate-unveils-new-storage-solutions\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421226\" data-ts=\"1546896512\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GRUB\" target=\"_blank\">GRUB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421226-angiplus-1_3-rdfnminus-0_5-after-needham-coverage-starts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ANGI +1.3%, RDFN -0.5% after Needham coverage starts</a></h4><ul>   <li>ANGI Homeservices is <font color=\"green\">up 1.3%</font> after hours following an update on service providers where Needham has initiated the company at Buy.</li>    <li>The firm has a price target of $23, implying 49.2% upside.</li>    <li>It's Neutral in starts on other providers: The firm has launched coverage on GrubHub (NYSE:<a href='https://seekingalpha.com/symbol/GRUB' title='GrubHub Inc.'>GRUB</a>) at Hold and Yelp (NYSE:<a href='https://seekingalpha.com/symbol/YELP' title='Yelp'>YELP</a>) at Hold. GrubHub <font color=\"green\">rose 5.3%</font> during the regular session.</li>    <li>In online real estate services, Needham has started Zillow (<a href='https://seekingalpha.com/symbol/Z' title='Zillow Group, Inc.'>Z</a>, <a href='https://seekingalpha.com/symbol/ZG' title='Zillow Group, Inc.'>ZG</a>) at Hold and Redfin (NASDAQ:<a href='https://seekingalpha.com/symbol/RDFN' title='Redfin'>RDFN</a>) at Underperform. <a href='https://seekingalpha.com/symbol/RDFN' title='Redfin'>RDFN</a> is <font color=\"red\">off 0.5%</font> in postmarket action.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3421226\" data-linked=\"ANGI +1.3%, RDFN -0.5% after Needham coverage starts\" data-tweet=\"$GRUB $GRUB $YELP - ANGI +1.3%, RDFN -0.5% after Needham coverage starts https://seekingalpha.com/news/3421226-angiplus-1_3-rdfnminus-0_5-after-needham-coverage-starts?source=tweet\" data-url=\"https://seekingalpha.com/news/3421226-angiplus-1_3-rdfnminus-0_5-after-needham-coverage-starts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421215\" data-ts=\"1546895717\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NLY\" target=\"_blank\">NLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421215-annaly-capitalminus-2_7-on-plans-for-75m-share-public-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Annaly Capital -2.7% on plans for 75M-share public offering</a></h4><ul><li>Annaly Capital Management (NYSE:<a href='https://seekingalpha.com/symbol/NLY' title='Annaly Capital Management, Inc.'>NLY</a>) <font color=\"red\">sinks 2.7%</font> in after-hours trading after announcing <a href=\"https://seekingalpha.com/pr/17372665-annaly-capital-management-inc-announces-public-offering-common-stock\" target=\"_blank\">plans to sell 75M shares</a> of common stock in a public offering.</li><li>Greenshoe option for an additional 11.25M shares.</li><li>Net proceeds for acquiring targeted assets under its capital allocation policy; also for general corporate purposes, which may included paying down obligations and other working capital items.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3389597-annaly-capital-management-lower-2_8-percent-announcing-pricing-common-stock\" target=\"_blank\">Annaly Capital Management lower 2.8% on announcing pricing of common stock</a> (Sept. 12, 2018)</li></ul><div class=\"tiny-share-widget\" data-id=\"3421215\" data-linked=\"Annaly Capital -2.7% on plans for 75M-share public offering\" data-tweet=\"$NLY - Annaly Capital -2.7% on plans for 75M-share public offering https://seekingalpha.com/news/3421215-annaly-capitalminus-2_7-on-plans-for-75m-share-public-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3421215-annaly-capitalminus-2_7-on-plans-for-75m-share-public-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>48&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421213\" data-ts=\"1546895577\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LEU\" target=\"_blank\">LEU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421213-centrus-energyplus-21-on-anticipated-115m-energy-department-contract\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Centrus Energy +21% on anticipated $115M Energy Department contract</a></h4><ul><li>Centrus Energy (<a href='https://seekingalpha.com/symbol/LEU' title='Centrus Energy Corp.'>LEU</a> <font color=\"green\">+21.5%</font>) surged in today's trade after the U.S. Energy Department announced plans to spend $115M on a project to help <a href=\"https://www.wsj.com/articles/energy-department-initiative-aims-to-keep-u-s-competitive-on-nuclear-plant-fuel-11546893816\" target=\"_blank\">develop advanced fuels for next-generation reactors</a>.</li><li>DoE officials say they plan to award the contract to Centrus's American Centrifuge Operating unit unless rival companies can make a compelling case by Jan. 22.</li><li>Russia is the only country capable of producing the higher-enriched uranium the DoE\u2019s new program would produce; without it, the U.S. risks being left out of the global industry\u2019s next stage, says Deputy Energy Secretary Dan Brouillette.</li></ul><div class=\"tiny-share-widget\" data-id=\"3421213\" data-linked=\"Centrus Energy +21% on anticipated $115M Energy Department contract\" data-tweet=\"$LEU - Centrus Energy +21% on anticipated $115M Energy Department contract https://seekingalpha.com/news/3421213-centrus-energyplus-21-on-anticipated-115m-energy-department-contract?source=tweet\" data-url=\"https://seekingalpha.com/news/3421213-centrus-energyplus-21-on-anticipated-115m-energy-department-contract\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:12 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421202\" data-ts=\"1546894782\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNK\" target=\"_blank\">MNK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421202-mallinckrodt-to-spin-out-generics-business-in-h2-shares-up-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mallinckrodt to spin out generics business in H2; shares up 6%</a></h4><ul><li>Mallinckrodt (<a href='https://seekingalpha.com/symbol/MNK' title='Mallinckrodt PLC'>MNK</a> <font color=\"green\">+5.5%</font>) CEO Mark Trudeau says his company expects to spin out its generic business in H2 or earlier, adding that he intends to raise new debt for the standalone company consistent with a 3.5x - 4.0x leverage ratio.</li><li>In the meantime, management's priority will be to reduce debt on the enterprise's balance sheet.</li><li>Most of the manufacturing assets will go with the spin-out.</li><li>Detailed 2019 guidance will be released with Q4 results in late February.</li><li>Source: Bloomberg</li><li>#JPM19</li></ul><div class=\"tiny-share-widget\" data-id=\"3421202\" data-linked=\"Mallinckrodt to spin out generics business in H2; shares up 6%\" data-tweet=\"$MNK - Mallinckrodt to spin out generics business in H2; shares up 6% https://seekingalpha.com/news/3421202-mallinckrodt-to-spin-out-generics-business-in-h2-shares-up-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3421202-mallinckrodt-to-spin-out-generics-business-in-h2-shares-up-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421198\" data-ts=\"1546894483\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GE\" target=\"_blank\">GE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421198-geplus-6-for-sixth-straight-gain-talk-of-jet-leasing-unit-deal-prompts-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GE +6% for sixth straight gain; talk of jet leasing unit deal prompts upgrade</a></h4><ul><li>General Electric (<a href='https://seekingalpha.com/symbol/GE' title='General Electric'>GE</a> <font color=\"green\">+6%</font>) pushes forward to its sixth straight gains and its best level in two months on reports that Apollo Global <a href=\"https://seekingalpha.com/news/3420800-report-apollo-considering-bid-ges-jet-leasing-business\" target=\"_blank\">will bid to buy all or part</a> of GE Capital Aviation Services, despite some <a href=\"https://seekingalpha.com/news/3421067-analysts-skeptical-potential-ge-apollo-jet-leasing-deal\" target=\"_blank\">analyst skepticism</a>.</li><li>CFRA analyst Jim Corridore <a href=\"https://www.marketwatch.com/story/ges-stock-surges-toward-6th-straight-gain-after-reports-of-jet-leasing-business-sale-prompts-upgrade-2019-01-07\" target=\"_blank\">upgrades GE to Buy from Hold</a> and raises his price target to $11, saying \"with GE preparing to spin off healthcare and sell off its share in Baker Hughes, we think this news could provide a path to fix GE's highly leveraged balance sheet.\"</li><li>Meanwhile, J.P. Morgan bear Stephen Tusa believes a sale would not prove the \"silver bullet\" to leverage issues that bulls expect, but says the time likely is approaching where GE will provide something \"more tangible, <a href=\"https://thefly.com/thestreet/realmoney/index.php/GEid2844459/GE-JPMorgan-sees-GE-providing-something-more-tangible-soon-keeps--target\" target=\"_blank\">perhaps shrinking the balance sheet</a>,\" that will make the company easier to value.</li><li>However, related dilution, combined with a full \"cleanse\" of the accounting structure, should result in a \"substantially lower run rate fundamental anchor than many appreciate,\" Tusa says.</li></ul><div class=\"tiny-share-widget\" data-id=\"3421198\" data-linked=\"GE +6% for sixth straight gain; talk of jet leasing unit deal prompts upgrade\" data-tweet=\"$GE - GE +6% for sixth straight gain; talk of jet leasing unit deal prompts upgrade https://seekingalpha.com/news/3421198-geplus-6-for-sixth-straight-gain-talk-of-jet-leasing-unit-deal-prompts-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3421198-geplus-6-for-sixth-straight-gain-talk-of-jet-leasing-unit-deal-prompts-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:54 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>37&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421197\" data-ts=\"1546894380\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VIA\" target=\"_blank\">VIA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421197-fox-cbs-ceo-search-snags-candidates-drop-out\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fox: CBS CEO search snags as candidates drop out</a></h4><ul>   <li>CBS (<a href=\"http://seekingalpha.com/symbol/CBS\" target=\"_blank\">CBS</a> <font color=\"green\">+1.3%</font>) is losing some potential CEO candidates as they choose to drop out, though that's not slowing the company's timetable, Fox Business says.</li>    <li>The board still looks to choose a permanent successor to ex-CEO Les Moonves by the end of this quarter, Charlie Gasparino is saying, though there's \"somewhat of a snag\" as it's having a difficult time finding someone who both wants the job and is qualified.</li>    <li>And that CEO hiring could be complicated by parallel moves to find a merger partner (discussions that always include Viacom (<a href='https://seekingalpha.com/symbol/VIA' title='Viacom Inc.'>VIA</a> <font color=\"green\">+6.3%</font>, <a href='https://seekingalpha.com/symbol/VIAB' title='Viacom Inc.'>VIAB</a> <font color=\"green\">+4.9%</font>)), Fox says.</li><li>Even if someone becomes the CEO this quarter, \"he may not be CEO for very long,\" Gasparino says.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3421060-report-cbs-seeking-ceo-also-run-viacom\" target=\"_blank\">Report: CBS seeking CEO who could also run Viacom</a> (Jan. 07 2019)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3421197\" data-linked=\"Fox: CBS CEO search snags as candidates drop out\" data-tweet=\"$VIA $VIA $VIAB - Fox: CBS CEO search snags as candidates drop out https://seekingalpha.com/news/3421197-fox-cbs-ceo-search-snags-candidates-drop-out?source=tweet\" data-url=\"https://seekingalpha.com/news/3421197-fox-cbs-ceo-search-snags-candidates-drop-out\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421196\" data-ts=\"1546894310\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEVA\" target=\"_blank\">TEVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421196-teva-outlook-on-stable-prices-buoys-generics\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Teva outlook on stable prices buoys generics</a></h4><ul><li>Generic drug makers are in the green after Teva Pharmaceutical Industries (<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a> <font color=\"green\">+1.9%</font>) chief Kåre Schultz stated that he sees stable prices this year, a welcome view considering the downward pressure last year. He made the comment during his presentation at the JP Morgan Healthcare Conference.</li><li>Selected tickers: (<a href='https://seekingalpha.com/symbol/ACET' title='Aceto Corporation'>ACET</a> <font color=\"green\">+4.8%</font>)(<a href='https://seekingalpha.com/symbol/ACRS' title='Aclaris Therapeutics'>ACRS</a> <font color=\"green\">+2.2%</font>)(<a href='https://seekingalpha.com/symbol/AKRX' title='Akorn, Inc.'>AKRX</a> <font color=\"green\">+6.8%</font>)(<a href='https://seekingalpha.com/symbol/AMRX' title='Amneal Pharmaceuticals, Inc.'>AMRX</a> <font color=\"green\">+0.2%</font>)(<a href='https://seekingalpha.com/symbol/ANIP' title='ANI Pharmaceuticals, Inc.'>ANIP</a> <font color=\"green\">+3.2%</font>)(<a href='https://seekingalpha.com/symbol/BHC' title='Bausch Health Companies Inc.'>BHC</a> <font color=\"green\">+5.6%</font>)(<a href='https://seekingalpha.com/symbol/CHRS' title='Coherus BioSciences'>CHRS</a> <font color=\"green\">+17.5%</font>)(<a href='https://seekingalpha.com/symbol/ENDP' title='Endo International plc'>ENDP</a> <font color=\"green\">+10%</font>)(<a href='https://seekingalpha.com/symbol/LCI' title='Lannett Company, Inc'>LCI</a> <font color=\"green\">+21.3%</font>)(<a href='https://seekingalpha.com/symbol/MNK' title='Mallinckrodt PLC'>MNK</a> <font color=\"green\">+5.7%</font>)(<a href='https://seekingalpha.com/symbol/MYL' title='Mylan Inc'>MYL</a> <font color=\"green\">+3.5%</font>)(<a href='https://seekingalpha.com/symbol/PRGO' title='Perrigo Company'>PRGO</a> <font color=\"green\">+3.9%</font>)(<a href='https://seekingalpha.com/symbol/TLGT' title='Teligent, Inc.'>TLGT</a> <font color=\"green\">+7%</font>)</li><li><div>#JPM19</div></li></ul><div class=\"tiny-share-widget\" data-id=\"3421196\" data-linked=\"Teva outlook on stable prices buoys generics\" data-tweet=\"$TEVA $TEVA $ACET - Teva outlook on stable prices buoys generics https://seekingalpha.com/news/3421196-teva-outlook-on-stable-prices-buoys-generics?source=tweet\" data-url=\"https://seekingalpha.com/news/3421196-teva-outlook-on-stable-prices-buoys-generics\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421192\" data-ts=\"1546893810\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XNCR\" target=\"_blank\">XNCR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421192-xencor-regains-rights-to-bispecific-antibody-from-novartis-shares-up-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Xencor regains rights to bispecific antibody from Novartis; shares up 4%</a></h4><ul><li>Xencor (<a href='https://seekingalpha.com/symbol/XNCR' title='Xencor, Inc.'>XNCR</a> <font color=\"green\">+3.9%</font>) will <a href=\"https://seekingalpha.com/pr/17371644-xencor-regains-ex-u-s-commercial-rights-xmab-13676-cd20-x-cd3-bispecific-antibody\" target=\"_blank\">regain </a>the ex-U.S. rights to XmAB13676, a CD20 x CD3 bispecific antibody, from Novartis (<a href='https://seekingalpha.com/symbol/NVS' title='Novartis AG'>NVS</a> <font color=\"red\">-1.2%</font>) effective June 20. NVS backed away from the candidate due to new strategic priorities.</li><li>Preliminary data from a Phase 1 study in patients with B-cell cancers should be available this year.</li><li>The companies will continue to collaborate on developing XmAb14045. It owns U.S. rights while NVS owns ex-U.S. rights.</li></ul><div class=\"tiny-share-widget\" data-id=\"3421192\" data-linked=\"Xencor regains rights to bispecific antibody from Novartis; shares up 4%\" data-tweet=\"$XNCR $XNCR $NVS - Xencor regains rights to bispecific antibody from Novartis; shares up 4% https://seekingalpha.com/news/3421192-xencor-regains-rights-to-bispecific-antibody-from-novartis-shares-up-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3421192-xencor-regains-rights-to-bispecific-antibody-from-novartis-shares-up-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421187\" data-ts=\"1546893424\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTCT\" target=\"_blank\">PTCT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421187-ptc-therapeutics-2019-guidance-fails-to-lift-shares-down-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PTC Therapeutics 2019 guidance fails to lift shares, down 2%</a></h4><ul><li>PTC Therapeutics (<a href='https://seekingalpha.com/symbol/PTCT' title='PTC Therapeutics'>PTCT</a> <font color=\"red\">-1.9%</font>) is down on 25% higher volume following its <a href=\"https://seekingalpha.com/pr/17371612-ptc-therapeutics-provides-corporate-update-outlines-5-year-strategic-plan-2019-j-p-morgan\" target=\"_blank\">release </a>of <strong>2019 guidance</strong>.</li><li>Product revenues: $285M - 305M; R&amp;D and SG&amp;A expenses: $395M - 405M.</li><li><strong>2018 guidance</strong>: Translarna sales: ~$171M; Emflaza sales: ~$91M; cash and equivalents at year-end: ~$227M.</li><li>#JPM19</li></ul><div class=\"tiny-share-widget\" data-id=\"3421187\" data-linked=\"PTC Therapeutics 2019 guidance fails to lift shares, down 2%\" data-tweet=\"$PTCT - PTC Therapeutics 2019 guidance fails to lift shares, down 2% https://seekingalpha.com/news/3421187-ptc-therapeutics-2019-guidance-fails-to-lift-shares-down-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3421187-ptc-therapeutics-2019-guidance-fails-to-lift-shares-down-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:37 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421183\" data-ts=\"1546892692\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTGR\" target=\"_blank\">NTGR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421183-netgear-updates-orbi-wi-fi-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NetGear updates Orbi with Wi-Fi 6</a></h4><ul><li>NetGear (<a href='https://seekingalpha.com/symbol/NTGR' title='NETGEAR, Inc.'>NTGR</a> <font color='green'>+2%</font>) <a href=\"https://seekingalpha.com/pr/17372553-leading-new-era-wi-fi-netgear-announces-orbi-mesh-wi-fi-system-using-wi-fi-6-specifically\" target=\"_blank\">announces</a> the upcoming expansion of its Orbi Mesh Wi-Fi System to include the Wi-Fi 6-enabled Orbi Whole Home Wi-Fi System.</li><li>The Mesh Wi-Fi System will gain 1024 QAM with a 4x4 Wi-Fi 6 backhaul, increasing the speeds, coverage and capacity.</li><li>Orbi with Wi-Fi 6 will launch in the second half of 2019.</li></ul><div class=\"tiny-share-widget\" data-id=\"3421183\" data-linked=\"NetGear updates Orbi with Wi-Fi 6\" data-tweet=\"$NTGR - NetGear updates Orbi with Wi-Fi 6 https://seekingalpha.com/news/3421183-netgear-updates-orbi-wi-fi-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3421183-netgear-updates-orbi-wi-fi-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:24 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421182\" data-ts=\"1546892574\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421182-stocks-slip-from-session-highs-in-late-trading\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stocks slip from session highs in late trading</a></h4><ul><li>U.S. stocks ease off from session highs. The S&amp;P, earlier up as much as 1.2%, pares down to a<font color=\"green\"> 0.9% increase</font>.</li><li>Nasdaq <font color=\"green\">+1.4%</font> and Dow <font color=\"green\">+0.6%</font>.</li><li>By sector, services (<font color=\"green\">+1.8%</font>) and conglomerates (<font color=\"green\">+1.3%</font>) lead, with utilities (<font color=\"red\">-0.6%</font>) and consumer goods (<font color=\"green\">+0.4%</font>) lagging.</li><li>Oil <font color=\"green\">increases 1.5%</font> to $48.66/bbl and gold <font color=\"green\">+0.3%</font> to $1,289.10/ounce.</li><li>10-year Treasury yield rises 2 basis points to 2.69%.</li></ul><div class=\"tiny-share-widget\" data-id=\"3421182\" data-linked=\"Stocks slip from session highs in late trading\" data-tweet=\"Stocks slip from session highs in late trading https://seekingalpha.com/news/3421182-stocks-slip-from-session-highs-in-late-trading?source=tweet\" data-url=\"https://seekingalpha.com/news/3421182-stocks-slip-from-session-highs-in-late-trading\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421179\" data-ts=\"1546892430\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OCUL\" target=\"_blank\">OCUL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421179-ocular-therapeutix-teams-up-purdue-pharma-to-develop-new-pain-meds\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ocular Therapeutix teams up with Purdue Pharma to develop new pain meds</a></h4><ul><li>Ocular Therapeutix (<a href='https://seekingalpha.com/symbol/OCUL' title='Ocular Therapeutix'>OCUL</a> <font color=\"red\">-2.8%</font>) <a href=\"https://seekingalpha.com/pr/17371947-purdue-pharma-l-p-ocular-therapeutix-inc-announce-initiation-collaborative-research\" target=\"_blank\">initiates </a>research with Purdue Pharma L.P. to determine the compatibility of the latter's non-opioid molecules with its bioresorbable hydrogel-based technology with the ultimate goal of developing new pain medications.</li><li>OCUL will initiate formulation testing aimed at advancing candidates to a point where efficacy can be assessed.</li><li>Financial terms are not disclosed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3421179\" data-linked=\"Ocular Therapeutix teams up with Purdue Pharma to develop new pain meds\" data-tweet=\"$OCUL - Ocular Therapeutix teams up with Purdue Pharma to develop new pain meds https://seekingalpha.com/news/3421179-ocular-therapeutix-teams-up-purdue-pharma-to-develop-new-pain-meds?source=tweet\" data-url=\"https://seekingalpha.com/news/3421179-ocular-therapeutix-teams-up-purdue-pharma-to-develop-new-pain-meds\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421181\" data-ts=\"1546892408\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSLA\" target=\"_blank\">TSLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421181-tesla-starts-taking-model-3-orders-in-china\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tesla starts taking Model 3 orders in China</a></h4><ul> <li>Tesla (NASDAQ:<a href='https://seekingalpha.com/symbol/TSLA' title='Tesla, Inc.'>TSLA</a>) says customers in China can now <a href=\"https://twitter.com/Tesla/status/1082367348625928192\" target=\"_blank\">order</a> a Model 3 vehicle off the company's <a href=\"https://3.tesla.cn/model3/design#battery\" target=\"_blank\">website</a>.</li> <li>The announcement follows the groundbreaking earlier today of the Gigfactory in Shanghai.</li> <li>Last week, Tesla said it expected to start making Model 3 deliveries in the region during March.</li> <li>Shares of Tesla are <font color=\"green\">up 5.25%</font> to $334.38 vs. a 52-week trading range of $244.59 to $387.46.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3421181\" data-linked=\"Tesla starts taking Model 3 orders in China\" data-tweet=\"$TSLA - Tesla starts taking Model 3 orders in China https://seekingalpha.com/news/3421181-tesla-starts-taking-model-3-orders-in-china?source=tweet\" data-url=\"https://seekingalpha.com/news/3421181-tesla-starts-taking-model-3-orders-in-china\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>131&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421178\" data-ts=\"1546892076\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EHC\" target=\"_blank\">EHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421178-encompass-health-up-2-on-updated-2018-guidance-and-2019-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Encompass Health up 2% on updated 2018 guidance and 2019 outlook</a></h4><ul><li>Encompass Health (<a href='https://seekingalpha.com/symbol/EHC' title='Encompass Health Corporation'>EHC</a> <font color=\"green\">+1.9%</font>) is up on modestly higher volume after updating its 2018 guidance and providing its <a href=\"https://www.sec.gov/Archives/edgar/data/785161/000078516119000003/january2019jpmorganform8-k.htm\" target=\"_blank\">outlook</a> for this year.</li><li><strong>2018</strong>: Revenues: $4,260M - 4,280M from $4,520M - 4,300M; non-GAAP EBITDA: $890M - 895M from $880M - 890M; non-GAAP EPS: $3.62 - 3.66 from $3.55 3.63.</li><li><strong>2019</strong>: Revenues: $4,500M - 4,600; non-GAAP EBITDA: $925M - 945M; non-GAAP EPS: $3.71 - 3.85.</li><li>#JPM19</li></ul><div class=\"tiny-share-widget\" data-id=\"3421178\" data-linked=\"Encompass Health up 2% on updated 2018 guidance and 2019 outlook\" data-tweet=\"$EHC - Encompass Health up 2% on updated 2018 guidance and 2019 outlook https://seekingalpha.com/news/3421178-encompass-health-up-2-on-updated-2018-guidance-and-2019-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3421178-encompass-health-up-2-on-updated-2018-guidance-and-2019-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:14 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421176\" data-ts=\"1546891886\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MAT\" target=\"_blank\">MAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421176-mattel-extends-bounce-off-52-week-low\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mattel extends bounce off 52-week low</a></h4><ul> <li>Mattel (NASDAQ:<a href='https://seekingalpha.com/symbol/MAT' title='Mattel, Inc.'>MAT</a>) is <font color=\"green\">up another 7.49%</font> after a strong move on Friday when shares bounced from a 52-week low.</li> <li>Over the weekend, the company <a href=\"https://seekingalpha.com/pr/17371093-mattel-announces-global-licensing-agreement-global-boy-band-bts\" target=\"_blank\">announced</a> a new worldwide licensing agreement with a popular South Korean boy band.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3421176\" data-linked=\"Mattel extends bounce off 52-week low\" data-tweet=\"$MAT - Mattel extends bounce off 52-week low https://seekingalpha.com/news/3421176-mattel-extends-bounce-off-52-week-low?source=tweet\" data-url=\"https://seekingalpha.com/news/3421176-mattel-extends-bounce-off-52-week-low\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:11 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421173\" data-ts=\"1546891457\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VRAY\" target=\"_blank\">VRAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421173-viewray-files-for-250m-mixed-shelf-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ViewRay files for $250M mixed shelf offering</a></h4><ul><li>ViewRay (<a href='https://seekingalpha.com/symbol/VRAY' title='ViewRay'>VRAY</a> <font color='green'>+7.5%</font>) has filed a <a href=\"https://www.sec.gov/Archives/edgar/data/1597313/000119312519003021/d678871ds3.htm\" target=\"_blank\">prospectus </a>for a $250M mixed shelf offering.</li></ul><div class=\"tiny-share-widget\" data-id=\"3421173\" data-linked=\"ViewRay files for $250M mixed shelf offering\" data-tweet=\"$VRAY - ViewRay files for $250M mixed shelf offering https://seekingalpha.com/news/3421173-viewray-files-for-250m-mixed-shelf-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3421173-viewray-files-for-250m-mixed-shelf-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421171\" data-ts=\"1546891309\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421171-semis-outperform-ahead-of-ces\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Semis outperform ahead of CES</a></h4><ul><li>The Philadelphia Semiconductor Index gains <font color=\"green\">2.2% </font>compared to the tech sector (NYSEARCA:<a href='https://seekingalpha.com/symbol/XLK' title='Technology Select Sector SPDR ETF'>XLK</a>) <font color=\"green\">+0.7%</font> ahead of CES 2019 with Nvidia <font color=\"green\">+5.7%</font> and AMD <font color=\"green\">+7.6%</font> leading the way after the former's <a href=\"https://seekingalpha.com/news/3420876-nvidia-introduces-new-gaming-chip\" target=\"_blank\">presentation yesterday</a> that included a new gaming chip.</li><li>AMD chief Lisa Su <a href=\"https://seekingalpha.com/pr/17368895-amd-president-ceo-dr-lisa-su-keynote-ces-2019\" target=\"_blank\">will present</a> a keynote address on Wednesday at 9 AM PT.</li><li>Related semiconductor ETFs: <a href='https://seekingalpha.com/symbol/SOXL' title='Direxion Daily Semiconductor 3x Bull Shares ETF'>SOXL</a>, <a href='https://seekingalpha.com/symbol/SOXX' title='iShares PHLX SOX Semiconductor Sector Index ETF'>SOXX</a>, <a href='https://seekingalpha.com/symbol/SMH' title='VanEck Vectors Semiconductor ETF'>SMH</a>, <a href='https://seekingalpha.com/symbol/USD' title='ProShares Ultra Semiconductors ETF'>USD</a>, <a href='https://seekingalpha.com/symbol/PSI' title='Invesco Dynamic Semiconductors Portfolio ETF'>PSI</a>, <a href='https://seekingalpha.com/symbol/XSD' title='SPDR S&P Semiconductor ETF'>XSD</a>, <a href='https://seekingalpha.com/symbol/SOXS' title='Direxion Daily Semiconductor 3x Bear Shares ETF'>SOXS</a>, <a href='https://seekingalpha.com/symbol/SSG' title='ProShares UltraShort Semiconductors ETF'>SSG</a>, <a href='https://seekingalpha.com/symbol/FTXL' title='First Trust Nasdaq Semiconductor ETF'>FTXL</a>, <a href='https://seekingalpha.com/symbol/XTH' title='SPDR S&P Technology Hardware ETF'>XTH</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3421171\" data-linked=\"Semis outperform ahead of CES\" data-tweet=\"$XLK $SOXL $SOXX - Semis outperform ahead of CES https://seekingalpha.com/news/3421171-semis-outperform-ahead-of-ces?source=tweet\" data-url=\"https://seekingalpha.com/news/3421171-semis-outperform-ahead-of-ces\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421170\" data-ts=\"1546891308\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STML\" target=\"_blank\">STML</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421170-stemline-files-elzonris-marketing-application-europe-for-bpdcn-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stemline files Elzonris marketing application Europe for BPDCN; shares up 2%</a></h4><ul><li>Stemline Therapeutics (<a href='https://seekingalpha.com/symbol/STML' title='Stemline Therapeutics'>STML</a> <font color=\"green\">+2.1%</font>) has <a href=\"https://seekingalpha.com/pr/17372103-stemline-therapeutics-announces-submission-european-marketing-authorization-application-maa\" target=\"_blank\">filed </a>a marketing application in Europe seeking approval for ELZONRIS (tagraxofusp) for <a href=\"https://www.uptodate.com/contents/blastic-plasmacytoid-dendritic-cell-neoplasm\" target=\"_blank\">blastic plasmacytoid dendritic cell neoplasm</a> &#40;BPDCN&#41;, a rare type of blood cancer. The CD123-directed cytotoxin has accelerated view status.</li></ul><div class=\"tiny-share-widget\" data-id=\"3421170\" data-linked=\"Stemline files Elzonris marketing application Europe for BPDCN; shares up 2%\" data-tweet=\"$STML - Stemline files Elzonris marketing application Europe for BPDCN; shares up 2% https://seekingalpha.com/news/3421170-stemline-files-elzonris-marketing-application-europe-for-bpdcn-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3421170-stemline-files-elzonris-marketing-application-europe-for-bpdcn-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421169\" data-ts=\"1546891287\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LXFT\" target=\"_blank\">LXFT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421169-plug-maxr-lxft-among-tech-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PLUG, MAXR &amp; LXFT among tech movers</a></h4><ul><li><strong>Gainers: </strong>Luxoft Holding (NYSE:<a href='https://seekingalpha.com/symbol/LXFT' title='Luxoft Holding Inc'>LXFT</a>) <font color=\"green\">+82%</font>. CLPS Incorporation (NASDAQ:<a href='https://seekingalpha.com/symbol/CLPS' title='CLPS, Inc'>CLPS</a>) <font color=\"green\">+33%</font>. Plug Power (NASDAQ:<a href='https://seekingalpha.com/symbol/PLUG' title='Plug Power, Inc.'>PLUG</a>) <font color=\"green\">+14%</font>. SilverSun Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/SSNT' title='SilverSun Technologies, Inc.'>SSNT</a>) <font color=\"green\">+11%</font>. i3 Verticals (NASDAQ:<a href='https://seekingalpha.com/symbol/IIIV' title='i3 Verticals'>IIIV</a>) <font color=\"green\">+11%</font>.</li> <li><strong>Losers: </strong>Maxar Technologies (NYSE:<a href='https://seekingalpha.com/symbol/MAXR' title='Maxar Technologies Inc'>MAXR</a>) <font color=\"red\">-31%</font>. FTE Networks (NYSEMKT:<a href='https://seekingalpha.com/symbol/FTNW' title='FTE Networks, Inc.'>FTNW</a>) <font color=\"red\">-14%</font>. Gridsum Holding (NASDAQ:<a href='https://seekingalpha.com/symbol/GSUM' title='Gridsum Holding'>GSUM</a>) <font color=\"red\">-13%</font>. Uxin Limited (NASDAQ:<a href='https://seekingalpha.com/symbol/UXIN' title='Uxin'>UXIN</a>) <font color=\"red\">-9%</font>. Boxlight Corporation (NASDAQ:<a href='https://seekingalpha.com/symbol/BOXL' title='Boxlight'>BOXL</a>) <font color=\"red\">-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3421169\" data-linked=\"PLUG, MAXR &amp; LXFT among tech movers\" data-tweet=\"$LXFT $LXFT $CLPS - PLUG, MAXR &amp; LXFT among tech movers https://seekingalpha.com/news/3421169-plug-maxr-lxft-among-tech-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3421169-plug-maxr-lxft-among-tech-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421166\" data-ts=\"1546890675\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SBGL\" target=\"_blank\">SBGL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421166-sibanye-sees-earnings-hit-strike-gold-mines-drags-on\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sibanye sees earnings hit as strike at gold mines drags on</a></h4><ul><li>Sibanye-Stillwater (<a href='https://seekingalpha.com/symbol/SBGL' title='Sibanye-Stillwater'>SBGL</a> <font color='red'>-4.8%</font>) says the strike at its South African gold mines since November <a href=\"http://www.mining.com/web/sibanye-counts-hit-earnings-strike-gold-mines-drags/\" target=\"_blank\">may hurt earnings and revenues</a>, as inconsistent production at three mines has limited operations.</li><li>The strike will not force a restructuring of the affected mines, but there could be a review if the impact is severe, SBGL says.</li><li>Talks between the company and the AMCU union have made <a href=\"https://www.miningmx.com/trending/35496-prospect-high-amcu-strike-at-sibanye-stillwater-gold-mines-may-drag-on/\" target=\"_blank\">no progress</a> so far.</li><li>SBGL cannot afford a prolonged  production hiatus at its gold operations even though a rally in  palladium has provided some cushion, says Vunani Securities analyst Hurbey Geldenhuys.</li></ul><div class=\"tiny-share-widget\" data-id=\"3421166\" data-linked=\"Sibanye sees earnings hit as strike at gold mines drags on\" data-tweet=\"$SBGL - Sibanye sees earnings hit as strike at gold mines drags on https://seekingalpha.com/news/3421166-sibanye-sees-earnings-hit-strike-gold-mines-drags-on?source=tweet\" data-url=\"https://seekingalpha.com/news/3421166-sibanye-sees-earnings-hit-strike-gold-mines-drags-on\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421160\" data-ts=\"1546889567\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SRPT\" target=\"_blank\">SRPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421160-sarepta-advancing-dmd-pipeline-shares-down-9-on-soft-exondys-51-q4-sales\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sarepta advancing DMD pipeline; shares down 9% on soft Exondys 51 Q4 sales</a></h4><ul><li>At JPM19, Sarepta Therapeutics (<a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a> <font color=\"red\">-9%</font>) updated investors on its DMD line-up. Highlights:</li><li>SRP-4045 (casimersen): 45 biopsies to be run this quarter. If positive, a U.S. marketing application will be filed this year with the expectation of early 2020 approval.</li><li>Micro-Dystrophin gene therapy: Dosing in children began last month. Buildout of commercial supply in process. Pivotal study to start this year. Commercial supply to support dosing in H2.</li><li>Dosing underway in Limb-girdle muscular dystrophy. Biopsy data should be available this quarter.</li><li>MPS: Dosing to start this quarter in pivotal study run by Lysogene.</li><li>Source: Tweet from attendee @MauriceOnTW</li><li>Previously: <a href=\"https://seekingalpha.com/news/3421096-sarepta-5-percent-preliminary-exondys-51-sales\" target=\"_blank\">Sarepta down 5% on preliminary Exondys 51 sales</a> (Jan. 7)</li><li>#JPM19</li></ul><div class=\"tiny-share-widget\" data-id=\"3421160\" data-linked=\"Sarepta advancing DMD pipeline; shares down 9% on soft Exondys 51 Q4 sales\" data-tweet=\"$SRPT - Sarepta advancing DMD pipeline; shares down 9% on soft Exondys 51 Q4 sales https://seekingalpha.com/news/3421160-sarepta-advancing-dmd-pipeline-shares-down-9-on-soft-exondys-51-q4-sales?source=tweet\" data-url=\"https://seekingalpha.com/news/3421160-sarepta-advancing-dmd-pipeline-shares-down-9-on-soft-exondys-51-q4-sales\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421159\" data-ts=\"1546889536\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/T\" target=\"_blank\">T</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421159-btig-and-ts-fake-5g-still-provides-chance-to-pass-verizon\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BTIG: AT&amp;T&#39;s &#39;fake&#39; 5G still provides chance to pass Verizon</a></h4><ul>   <li>AT&amp;T (<a href=\"http://seekingalpha.com/symbol/T\" target=\"_blank\">T</a> <font color=\"green\">+2.6%</font>) has a real chance to <a href=\"https://www.btigresearch.com/wp-login.php?redirect_to=%2F2019%2F01%2F07%2Fheres-how-atts-fake-5g-could-unseat-verizons-network-dominance%2F\" target=\"_blank\">surpass Verizon</a> (<a href=\"http://seekingalpha.com/symbol/VZ\" target=\"_blank\">VZ</a> <font color=\"green\">+0.9%</font>) in network dominance thanks to deploying 60 MHz of faster spectrum this year, BTIG's Walt Piecyk says.</li>    <li>The two telecom giants are locked in an arms race to claim various \"firsts\" in the road to 5G -- where standards are still not final -- and AT&amp;T is marketing the new spectrum as \"5Ge,\" a move that's drawn criticism from the industry including <a href=\"https://www.theverge.com/2019/1/7/18172355/att-fake-5g-logo-rolling-out-samsung-lg?utm_campaign=theverge&amp;utm_content=chorus&amp;utm_medium=social&amp;utm_source=twitter\" target=\"_blank\">claims of \"fake 5G.\"</a></li>    <li>The spectrum may not be \"true\" 5G, but \"the bigger picture is that AT&amp;T's network is getting a big lift,\" Piecyk says.</li>    <li>\"The tech media can scold AT&amp;T for using 5Ge, but if implemented properly, the AT&amp;T customer should notice a material improvement in performance when the 5Ge tag appears on their phone,\" Piecyk writes.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3421159\" data-linked=\"BTIG: AT&amp;T&#39;s &#39;fake&#39; 5G still provides chance to pass Verizon\" data-tweet=\"$T $T $VZ - BTIG: AT&amp;T&#39;s &#39;fake&#39; 5G still provides chance to pass Verizon https://seekingalpha.com/news/3421159-btig-and-ts-fake-5g-still-provides-chance-to-pass-verizon?source=tweet\" data-url=\"https://seekingalpha.com/news/3421159-btig-and-ts-fake-5g-still-provides-chance-to-pass-verizon\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>85&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421155\" data-ts=\"1546888456\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VTL\" target=\"_blank\">VTL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421155-vital-therapies-to-acquire-immunic-ag-in-all-stock-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vital Therapies to acquire Immunic AG in all-stock deal</a></h4><ul><li>Vital Therapies (<a href='https://seekingalpha.com/symbol/VTL' title='Vital Therapies, Inc.'>VTL</a> <font color=\"red\">-6.8%</font>) has <a href=\"https://seekingalpha.com/pr/17371196-vital-therapies-immunic-therapeutics-announce-transaction-create-leading-inflammatory\" target=\"_blank\">agreed to acquire </a>all outstanding shares of Planegg-Martinsried, Germany-based Immunic AG, a developer of therapies for chronic inflammatory and autoimmune diseases.</li><li>The combined company, 11% owned by VTL shareholders and 89% owned by Immunic shareholders, will do business as Immunic and will trade on the Nasdaq global market. Prior to closing, VTL management will seek shareholder approval for a reverse stock split.</li></ul><div class=\"tiny-share-widget\" data-id=\"3421155\" data-linked=\"Vital Therapies to acquire Immunic AG in all-stock deal\" data-tweet=\"$VTL $IMUX - Vital Therapies to acquire Immunic AG in all-stock deal https://seekingalpha.com/news/3421155-vital-therapies-to-acquire-immunic-ag-in-all-stock-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3421155-vital-therapies-to-acquire-immunic-ag-in-all-stock-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421154\" data-ts=\"1546888157\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421154-amazon-key-comes-to-ring-garages-businesses\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amazon Key comes to Ring, garages, businesses</a></h4><ul><li>Amazon's (<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a> <font color='green'>+2.9%</font>) keyless parcel delivery service <a href=\"https://seekingalpha.com/pr/17372455-key-amazon-introduces-new-products-services-expand-secure-convenient-keyless-entry-offerings\" target=\"_blank\">expands</a> its offering for Prime customers.</li><li>Key for Garage works with CGI's myQ-connected garage door opener to allow remote garage monitoring and keyless deliveries. The service will launch in Q2.</li><li>Key for Business is a smart fob for delivery drivers taking packages to commercial and multi-unit residential properties. Building owners and managers can give the drivers controlled access for the deliveries. Key for Business is now available.</li><li>The Schlage Encode Smart WiFi Deadbolt is the first WiFi-enabled smart lock for Key and aimed at renters or others who don't want to use a hub or hardware for the Key experience. The deadbolt costs $249.99 (or $299.99 bundled with a Cloud Cam) and is available now for pre-order with shipments starting March 5.</li><li>Ring customers will be able to unlock Key-compatible smart locks from within the Ring app. The feature will launch in Q1.</li><li><a href=\"https://seekingalpha.com/search/?q=CES19&amp;tab=news\" target=\"_blank\">#CES19</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3421111-ring-launches-smart-peephole-security-lights\" target=\"_blank\">Ring launches smart peephole, security lights</a> (Jan. 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3421154\" data-linked=\"Amazon Key comes to Ring, garages, businesses\" data-tweet=\"$AMZN - Amazon Key comes to Ring, garages, businesses https://seekingalpha.com/news/3421154-amazon-key-comes-to-ring-garages-businesses?source=tweet\" data-url=\"https://seekingalpha.com/news/3421154-amazon-key-comes-to-ring-garages-businesses\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421152\" data-ts=\"1546887605\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MRTX\" target=\"_blank\">MRTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421152-mirati-up-7-on-clinical-collaboration-bmy-in-lung-cancer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mirati up 7% on clinical collaboration with BMY in lung cancer</a></h4><ul><li>Mirati Therapeutics (<a href='https://seekingalpha.com/symbol/MRTX' title='Mirati Therapeutics, Inc.'>MRTX</a> <font color=\"green\">+6.7%</font>) is up on below-average volume on the heels of its clinical <a href=\"https://seekingalpha.com/pr/17371777-mirati-announces-clinical-collaboration-bristol-myers-squibb-planned-phase-3-trial-non-small\" target=\"_blank\">collaboration </a>with Bristol-Myers Squibb (<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a> <font color=\"green\">+3.5%</font>) evaluating the combination of sitravatinib and Opdivo (nivolumab) for the second-line treatment of patients with non-small cell lung cancer &#40;NSCLC&#41; who have progressed after platinum-based chemo and a checkpoint inhibitor.</li><li>A Phase 3 study should launch in H1. Mirati will conduct the trial while BMY will supply product.</li></ul><div class=\"tiny-share-widget\" data-id=\"3421152\" data-linked=\"Mirati up 7% on clinical collaboration with BMY in lung cancer\" data-tweet=\"$MRTX $MRTX $BMY - Mirati up 7% on clinical collaboration with BMY in lung cancer https://seekingalpha.com/news/3421152-mirati-up-7-on-clinical-collaboration-bmy-in-lung-cancer?source=tweet\" data-url=\"https://seekingalpha.com/news/3421152-mirati-up-7-on-clinical-collaboration-bmy-in-lung-cancer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421150\" data-ts=\"1546887575\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QEP\" target=\"_blank\">QEP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421150-qep-resources-and-ion-geophysical-among-energy-materials-gainers-hi-crush-partners-sanchez\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">QEP Resources and ION Geophysical among Energy/Materials gainers; Hi-Crush Partners Sanchez Midstream Partners among losers</a></h4><ul><li><b>Gainers: </b>QEP Resources (NYSE:<a href='https://seekingalpha.com/symbol/QEP' title='QEP Resources, Inc.'>QEP</a>) <font color=\"green\">+42%</font>. ION Geophysical (NYSE:<a href='https://seekingalpha.com/symbol/IO' title='ION Geophysical Corporation'>IO</a>) <font color=\"green\">+24%</font>. Centrus Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/LEU' title='Centrus Energy Corp.'>LEU</a>) <font color=\"green\">+23%</font>. Ferroglobe (NASDAQ:<a href='https://seekingalpha.com/symbol/GSM' title='Ferroglobe PLC'>GSM</a>) <font color=\"green\">+22%</font>. Calumet Specialty Products Partners (NASDAQ:<a href='https://seekingalpha.com/symbol/CLMT' title='Calumet Specialty Products Partners, L.P.'>CLMT</a>) <font color=\"green\">+19%</font>.</li><li><b>Losers: </b>Hi-Crush Partners (NYSE:<a href='https://seekingalpha.com/symbol/HCLP' title='Hi-Crush Partners LP'>HCLP</a>) <font color=\"red\">-15%</font>. Sanchez Midstream Partners (NYSEMKT:<a href='https://seekingalpha.com/symbol/SNMP' title='Sanchez Midstream Partners LP'>SNMP</a>) <font color=\"red\">-9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3421150\" data-linked=\"QEP Resources and ION Geophysical among Energy/Materials gainers; Hi-Crush Partners Sanchez Midstream Partners among losers\" data-tweet=\"$QEP $QEP $IO - QEP Resources and ION Geophysical among Energy/Materials gainers; Hi-Crush Partners Sanchez Midstream Partners among losers https://seekingalpha.com/news/3421150-qep-resources-and-ion-geophysical-among-energy-materials-gainers-hi-crush-partners-sanchez?source=tweet\" data-url=\"https://seekingalpha.com/news/3421150-qep-resources-and-ion-geophysical-among-energy-materials-gainers-hi-crush-partners-sanchez\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:59 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421151\" data-ts=\"1546887567\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PBR\" target=\"_blank\">PBR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421151-petrobrasplus-4-brazil-government-said-to-award-14b-for-transfer-of-rights\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Petrobras +4% as Brazil government said to award $14B for transfer of rights</a></h4><ul><li>Petrobras (<a href='https://seekingalpha.com/symbol/PBR' title='Petrobras - Petroleo Brasileiro S.A.'>PBR</a> <font color=\"green\">+3.9%</font>) pops after Brazilian newspaper <em>Valor Economico</em> reported the government will <a href=\"https://www.reuters.com/article/us-petrobras-transfer-of-rights/petrobras-shares-rise-on-report-brazil-government-to-pay-oil-company-14-billion-idUSKCN1P11VN\" target=\"_blank\">pay $14B to the company</a> to settle a dispute about the offshore transfer of rights area.</li><li>The newspaper, which did not say how it obtained the information in its report, said the settlement has been discussed with new Pres. Bolsonaro\u2019s transition team.</li><li>The $14B is a \"good number,\" says Adeodato Volpi Netto, head of capital markets at Eleven Financial  Research, and would \"enable the materialization of different scenarios that depended on  this definition [of the amount the company will receive]. Many of the  company\u2019s investment programs and partnerships depended on an  understanding of its ability to work on leverage, cash management.\"</li><li>The dispute over the oil in question and the price of it dates back to  2010, when the Brazilian government granted PBR the right to  extract 5B barrels of oil and gas in the offshore Santos Basin.</li></ul><div class=\"tiny-share-widget\" data-id=\"3421151\" data-linked=\"Petrobras +4% as Brazil government said to award $14B for transfer of rights\" data-tweet=\"$PBR - Petrobras +4% as Brazil government said to award $14B for transfer of rights https://seekingalpha.com/news/3421151-petrobrasplus-4-brazil-government-said-to-award-14b-for-transfer-of-rights?source=tweet\" data-url=\"https://seekingalpha.com/news/3421151-petrobrasplus-4-brazil-government-said-to-award-14b-for-transfer-of-rights\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:59 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421146\" data-ts=\"1546887161\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MYGN\" target=\"_blank\">MYGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421146-myriad-genetics-down-11-on-bearish-reports\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Myriad Genetics down 11% on bearish reports</a></h4><ul><li>Myriad Genetics (<a href='https://seekingalpha.com/symbol/MYGN' title='Myriad Genetics, Inc.'>MYGN</a> <font color=\"red\">-11.4%</font>) is under pressure on almost 60% higher volume on the heels of two bearish reports from the Southern Investigative Reporting Foundation &#40;SIRF&#41;.</li><li>The <a href=\"http://sirf-online.org/2019/01/07/myriad-genetics-this-company-has-great-difficulties-telling-the-truth/\" target=\"_blank\">first </a>questions the usefulness of its GeneSight in major depressive disorder and management's over-selling of its benefits. The <a href=\"http://sirf-online.org/2019/01/07/myriad-genetics/\" target=\"_blank\">second </a>states that its revenues have been inflated is a loophole in Medicare reimbursement.</li></ul><div class=\"tiny-share-widget\" data-id=\"3421146\" data-linked=\"Myriad Genetics down 11% on bearish reports\" data-tweet=\"$MYGN - Myriad Genetics down 11% on bearish reports https://seekingalpha.com/news/3421146-myriad-genetics-down-11-on-bearish-reports?source=tweet\" data-url=\"https://seekingalpha.com/news/3421146-myriad-genetics-down-11-on-bearish-reports\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:52 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421142\" data-ts=\"1546886239\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ICE\" target=\"_blank\">ICE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421142-exchange-stocks-slide-after-report-of-new-competitor\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Exchange stocks slide after report of new competitor</a></h4><ul><li>NYSE-owner Intercontinental Exchange (<a href='https://seekingalpha.com/symbol/ICE' title='Intercontinental Exchange, Inc.'>ICE</a> <font color='red'>-1.7%</font>), Cboe Global Markets (<a href='https://seekingalpha.com/symbol/CBOE' title='CBOE Holdings'>CBOE</a> <font color='red'>-0.1%</font>), and Nasdaq (<a href='https://seekingalpha.com/symbol/NDAQ' title='Nasdaq Inc.'>NDAQ</a> <font color='red'>-2.4%</font>) slump after the <em>Wall Street Journal</em> reports that a group of nine financial firms are planning to start their own low-cost stock exchange.</li><li>Initial investors of the Members Exchange, or MEMX, include Morgan Stanley (<a href='https://seekingalpha.com/symbol/MS' title='Morgan Stanley'>MS</a> <font color='green'>+1.7%</font>), Fidelity Investments, Citadel Securities, Bank of America (<a href='https://seekingalpha.com/symbol/BAC' title='Bank of America Corporation'>BAC</a> <font color='green'>+0.6%</font>) Merrill Lynch, UBS (<a href='https://seekingalpha.com/symbol/UBS' title='UBS Group AG'>UBS</a> <font color='green'>+1.4%</font>), Virtu Financial (<a href='https://seekingalpha.com/symbol/VIRT' title='Virtu Financial, Inc.'>VIRT</a> <font color='red'>-0.3%</font>), Charles Schwab (<a href='https://seekingalpha.com/symbol/SCHW' title='The Charles Schwab Corporation'>SCHW</a> <font color='green'>+1.4%</font>), E*Trade Financial (<a href='https://seekingalpha.com/symbol/ETFC' title='E*TRADE Financial Corporation'>ETFC</a> <font color='green'>+1.8%</font>), and TD Ameritrade (<a href='https://seekingalpha.com/symbol/AMTD' title='TD Ameritrade Holding Corporation'>AMTD</a> <font color='green'>+0.9%</font>).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3420979-wall-street-firms-form-stock-exchange-rival-nyse-nasdaq-wsj\" target=\"_blank\">Wall Street firms to form stock exchange to rival NYSE, Nasdaq: WSJ</a> (Jan. 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3421142\" data-linked=\"Exchange stocks slide after report of new competitor\" data-tweet=\"$ICE $ICE $CBOE - Exchange stocks slide after report of new competitor https://seekingalpha.com/news/3421142-exchange-stocks-slide-after-report-of-new-competitor?source=tweet\" data-url=\"https://seekingalpha.com/news/3421142-exchange-stocks-slide-after-report-of-new-competitor\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421139\" data-ts=\"1546885479\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RDUS\" target=\"_blank\">RDUS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421139-radius-health-sees-u-s-sales-high-175m-this-year-shares-up-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Radius Health sees U.S. sales as high as $175M this year; shares up 3%</a></h4><ul><li>Radius Health (<a href='https://seekingalpha.com/symbol/RDUS' title='Radius Health, Inc.'>RDUS</a> <font color=\"green\">+3.2%</font>) <a href=\"https://seekingalpha.com/pr/17372067-radius-exceeds-2018-financial-guidance-provides-business-update-37th-annual-j-p-morgan\" target=\"_blank\">reports </a>that its has surpassed 2018 guidance with TYMLOS (abaloparatide) generating more than $98M in sales. A 5.9% price hike went into effect on January 1.</li><li>Quick assets totaled more than $220M at year-end.</li><li><strong>2019 outlook</strong>: TYMLOS sales of $155M - 175M (unchanged).</li><li>#JPM19</li></ul><div class=\"tiny-share-widget\" data-id=\"3421139\" data-linked=\"Radius Health sees U.S. sales as high as $175M this year; shares up 3%\" data-tweet=\"$RDUS - Radius Health sees U.S. sales as high as $175M this year; shares up 3% https://seekingalpha.com/news/3421139-radius-health-sees-u-s-sales-high-175m-this-year-shares-up-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3421139-radius-health-sees-u-s-sales-high-175m-this-year-shares-up-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421268\" data-ts=\"1546885278\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRN\" target=\"_blank\">TRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421268-trinity-industries-guardrail-case-turned-away-u-s-supreme-court\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trinity Industries guardrail case turned away by U.S. Supreme Court</a></h4><ul><li>Trinity Industries (<a href='https://seekingalpha.com/symbol/TRN' title='Trinity Industries Inc.'>TRN</a> <font color='green'>+2.6%</font>) is higher after the U.S. Supreme Court <a href=\"https://www.reuters.com/article/us-usa-court-trinity-inds/u-s-top-court-declines-to-take-up-trinity-industries-guardrail-case-idUSKCN1P11JB\" target=\"_blank\">denies a whistleblower's request</a> to revive a $663M judgment against the company in a lawsuit accusing TRN of failing to tell the U.S. government about changes made to a guardrail system that raised safety concerns.</li><li>The Court thus leaves in place a 2017 decision by the Fifth U.S. Circuit Court of Appeals overturning a 2014 verdict by a federal jury in Texas that found TRN had defrauded the government.</li><li><a href=\"https://seekingalpha.com/pr/17372101-trinity-industries-inc-announces-u-s-supreme-court-declines-review-fifth-circuit-court\" target=\"_blank\">TRN says</a> the ruling further confirms its long-standing belief that it did not violate the False Claims Act regarding the ET Plus highway end terminal system.</li></ul><div class=\"tiny-share-widget\" data-id=\"3421268\" data-linked=\"Trinity Industries guardrail case turned away by U.S. Supreme Court\" data-tweet=\"$TRN - Trinity Industries guardrail case turned away by U.S. Supreme Court https://seekingalpha.com/news/3421268-trinity-industries-guardrail-case-turned-away-u-s-supreme-court?source=tweet\" data-url=\"https://seekingalpha.com/news/3421268-trinity-industries-guardrail-case-turned-away-u-s-supreme-court\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421136\" data-ts=\"1546885014\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TGT\" target=\"_blank\">TGT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421136-retail-sector-breaks-higher\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Retail sector breaks higher</a></h4><ul> <li>Retail heavyweights Target (<a href='https://seekingalpha.com/symbol/TGT' title='Target Corporation'>TGT</a> <font color='green'>+5%</font>), Walmart (<a href='https://seekingalpha.com/symbol/WMT' title='Walmart Inc.'>WMT</a> <font color='green'>+1.8%</font>) and Macy's (<a href='https://seekingalpha.com/symbol/M' title='Macy&#39;s Inc.'>M</a> <font color='green'>+3.2%</font>) are outperforming broad market averages. A resumption of U.S.-China trade talks and more positive read-through on Friday's strong jobs report may be helping to bring some buyers back into the sector.</li> <li>Notable gainers include Ascena Retail (<a href='https://seekingalpha.com/symbol/ASNA' title='Ascena Retail Group Inc'>ASNA</a> <font color='green'>+11.7%</font>), Stein Mart (<a href='https://seekingalpha.com/symbol/SMRT' title='Stein Mart, Inc.'>SMRT</a> <font color='green'>+5.6%</font>), Boot Barn (<a href='https://seekingalpha.com/symbol/BOOT' title='Boot Barn Holdings'>BOOT</a> <font color='green'>+8.7%</font>), Abercrombie &amp; Fitch (<a href='https://seekingalpha.com/symbol/ANF' title='Abercrombie & Fitch'>ANF</a> <font color='green'>+7.5%</font>), The Children's Place (<a href='https://seekingalpha.com/symbol/PLCE' title='The Children&#39;s Place Retail Stores, Inc.'>PLCE</a> <font color='green'>+6.7%</font>), Gap (<a href='https://seekingalpha.com/symbol/GPS' title='The Gap, Inc.'>GPS</a> <font color='green'>+6.2%</font>), Express (<a href='https://seekingalpha.com/symbol/EXPR' title='Express, Inc.'>EXPR</a> <font color='green'>+5.3%</font>), Ross Stores (<a href='https://seekingalpha.com/symbol/ROST' title='Ross Stores, Inc.'>ROST</a> <font color='green'>+5.3%</font>), J. Jill (<a href='https://seekingalpha.com/symbol/JILL' title='J. Jill Group, Inc.'>JILL</a> <font color='green'>+4%</font>), L Brands (<a href='https://seekingalpha.com/symbol/LB' title='L Brands, Inc.'>LB</a> <font color='green'>+6.9%</font>), Ollie's Bargain Outlet Holdings (<a href='https://seekingalpha.com/symbol/OLLI' title='Ollie&#39;s Bargain Outlet Holdings'>OLLI</a> <font color='green'>+7.5%</font>), Dollar Tree (<a href='https://seekingalpha.com/symbol/DLTR' title='Dollar Tree, Inc.'>DLTR</a> <font color='green'>+6.1%</font>), Burlington Stores (<a href='https://seekingalpha.com/symbol/BURL' title='Burlington Stores, Inc'>BURL</a> <font color='green'>+3.3%</font>), Stitch Fix (<a href='https://seekingalpha.com/symbol/SFIX' title='Stitch Fix, Inc.'>SFIX</a> <font color='green'>+9%</font>), Farfetch (<a href='https://seekingalpha.com/symbol/FTCH' title='Farfetch'>FTCH</a> <font color='green'>+6.2%</font>) and The Container Store (<a href='https://seekingalpha.com/symbol/TCS' title='The Container Store Group, Inc.'>TCS</a> <font color='green'>+5.7%</font>).</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3421136\" data-linked=\"Retail sector breaks higher\" data-tweet=\"$TGT $TGT $WMT - Retail sector breaks higher https://seekingalpha.com/news/3421136-retail-sector-breaks-higher?source=tweet\" data-url=\"https://seekingalpha.com/news/3421136-retail-sector-breaks-higher\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421135\" data-ts=\"1546884802\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BLUE\" target=\"_blank\">BLUE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421135-bluebird-bio-up-8-on-car-t-development-deal-inhibrx\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bluebird bio up 8% on CAR-T development deal with Inhibrx</a></h4><ul><li>Bluebird bio (<a href='https://seekingalpha.com/symbol/BLUE' title='bluebird bio, Inc.'>BLUE</a> <font color=\"green\">+7.6%</font>) is up on below-average volume on the heels of its <a href=\"https://seekingalpha.com/pr/17371576-bluebird-bio-inhibrx-announce-collaboration-research-develop-commercialize-car-t-cell\" target=\"_blank\">announced </a>license agreement with privately held <a href=\"https://inhibrx.com/\" target=\"_blank\">Inhibrx</a> aimed at researching, developing and commercializing CAR-T therapies leveraging the latter's <a href=\"https://inhibrx.com/platforms/\" target=\"_blank\">single domain antibody platform</a>.</li><li>Under the terms of the partnership, BLUE will own exclusive global rights to certain unnamed CAR-T candidates for the potential treatment of a range of cancers. Inhibrx received $7M upfront and will be eligible to receive milestones and tiered royalties on net sales.</li></ul><div class=\"tiny-share-widget\" data-id=\"3421135\" data-linked=\"Bluebird bio up 8% on CAR-T development deal with Inhibrx\" data-tweet=\"$BLUE - Bluebird bio up 8% on CAR-T development deal with Inhibrx https://seekingalpha.com/news/3421135-bluebird-bio-up-8-on-car-t-development-deal-inhibrx?source=tweet\" data-url=\"https://seekingalpha.com/news/3421135-bluebird-bio-up-8-on-car-t-development-deal-inhibrx\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:13 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421130\" data-ts=\"1546884420\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JAGX\" target=\"_blank\">JAGX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421130-jaguar-health-up-13_4-on-4q18-commercial-sales-updates\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jaguar Health up 13.4% on 4Q18 commercial sales updates</a></h4><ul><li>Jaguar Health (<a href='https://seekingalpha.com/symbol/JAGX' title='Jaguar Animal Health, Inc.'>JAGX</a> <font color=\"green\">+13.4%</font>) <a href=\"https://seekingalpha.com/pr/17372023-jaguar-health-provides-fourth-quarter-2018-commercial-sales-updates\" target=\"_blank\">announces</a> commercial sales updates for 4Q18.</li><li>Mytesi gross sales for Q4 to be ~$2.18M, and Mytesi net sales to be ~$1.55M, representing growth of 37% Q/Q and 40% Q/Q. This exceeds 4Q17 gross and net sales by ~136% and ~123%.</li><li>FY18 gross sales are expected to be ~$5.726M, and Mytesi net sales are expected to be ~$4M.</li><li>The Company expects to file its Form 10-K in mid-February 2019.</li><li><a href=\"https://seekingalpha.com/cloudsearch/search?q=JPM19&amp;tab=news&amp;ticker=#1\" target=\"_blank\">#JPM19</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3421130\" data-linked=\"Jaguar Health up 13.4% on 4Q18 commercial sales updates\" data-tweet=\"$JAGX - Jaguar Health up 13.4% on 4Q18 commercial sales updates https://seekingalpha.com/news/3421130-jaguar-health-up-13_4-on-4q18-commercial-sales-updates?source=tweet\" data-url=\"https://seekingalpha.com/news/3421130-jaguar-health-up-13_4-on-4q18-commercial-sales-updates\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:07 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421127\" data-ts=\"1546884136\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALNY\" target=\"_blank\">ALNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421127-alnylam-up-9-on-q4-onpattro-sales\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alnylam up 9% on Q4 Onpattro sales</a></h4><ul><li>Alnylam Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ALNY' title='Alnylam Pharmaceuticals, Inc.'>ALNY</a> <font color=\"green\">+9.3%</font>) is up on below-average volume on the heels of its <a href=\"https://seekingalpha.com/pr/17371571-alnylam-announces-unaudited-fourth-quarter-2018-global-revenues-onpattro-patisiran-provides\" target=\"_blank\">announcement </a>of preliminary Q4 2018 results.</li><li>ONPATTRO (patisiran) sales were $11M - 12M. Over 200 patients in the U.S. and Europe are receiving commercial treatment.</li><li>Quick assets totaled ~$1.1B at year-end. Complete 2019 guidance will be released next month when it reports Q4 and 2018 full-year results.</li><li>#JPM19</li></ul><div class=\"tiny-share-widget\" data-id=\"3421127\" data-linked=\"Alnylam up 9% on Q4 Onpattro sales\" data-tweet=\"$ALNY - Alnylam up 9% on Q4 Onpattro sales https://seekingalpha.com/news/3421127-alnylam-up-9-on-q4-onpattro-sales?source=tweet\" data-url=\"https://seekingalpha.com/news/3421127-alnylam-up-9-on-q4-onpattro-sales\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421126\" data-ts=\"1546884012\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LGIH\" target=\"_blank\">LGIH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421126-lgi-homes-leads-financial-gainers-maiden-holdings-and-ezcorp-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">LGI Homes leads financial gainers; Maiden Holdings and EZCORP among losers</a></h4><ul><li><b>Gainers:</b> LGI Homes (NASDAQ:<a href='https://seekingalpha.com/symbol/LGIH' title='LGI Homes, Inc.'>LGIH</a>) <font color=\"green\">+12%</font>. EverQuote (NASDAQ:<a href='https://seekingalpha.com/symbol/EVER' title='EverQuote'>EVER</a>) <font color=\"green\">+8%</font>. Monroe Capital (NASDAQ:<a href='https://seekingalpha.com/symbol/MRCC' title='Monroe Capital'>MRCC</a>) <font color=\"green\">+8%</font>. Elevate Credit (NYSE:<a href='https://seekingalpha.com/symbol/ELVT' title='Elevate Credit'>ELVT</a>) <font color=\"green\">+7%</font>.</li><li><b>Losers:</b> EZCORP (NASDAQ:<a href='https://seekingalpha.com/symbol/EZPW' title='EZCORP, Inc.'>EZPW</a>) <font color=\"red\">-7%</font>. Maiden Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/MHLD' title='Maiden Hldgs Ltd'>MHLD</a>) <font color=\"red\">-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3421126\" data-linked=\"LGI Homes leads financial gainers; Maiden Holdings and EZCORP among losers\" data-tweet=\"$LGIH $LGIH $EVER - LGI Homes leads financial gainers; Maiden Holdings and EZCORP among losers https://seekingalpha.com/news/3421126-lgi-homes-leads-financial-gainers-maiden-holdings-and-ezcorp-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3421126-lgi-homes-leads-financial-gainers-maiden-holdings-and-ezcorp-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421123\" data-ts=\"1546883508\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SEDG\" target=\"_blank\">SEDG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421123-solaredge-to-buy-italian-e-mobility-firm-smre-for-77m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SolarEdge to buy Italian e-mobility firm SMRE for $77M</a></h4><ul><li>SolarEdge Technologies (<a href='https://seekingalpha.com/symbol/SEDG' title='SolarEdge Technologies'>SEDG</a> <font color='red'>-2.9%</font>) <a href=\"https://seekingalpha.com/pr/17371150-solaredge-enter-e-mobility-market-acquisition-s-m-r-e-spa\" target=\"_blank\">agrees to acquire</a> a 51% stake in Italian electric vehicle power train manufacturer SMRE for $77M in cash and shares.</li><li>Under Italian takeover rules, the Israeli company will be <a href=\"https://www.pv-magazine.com/2019/01/07/inverter-maker-solaredge-to-acquire-italian-ev-company/\" target=\"_blank\">obligated to make an offer</a> for the remaining 49% of SMRE, which is listed on Italy's AIM stock exchange.</li><li>SEDG expects the initial acquisition to reduce its cash balance by $39M, which will be reflected in Q1 cash flow and involve the issuance of ~1.1M common shares.</li></ul><div class=\"tiny-share-widget\" data-id=\"3421123\" data-linked=\"SolarEdge to buy Italian e-mobility firm SMRE for $77M\" data-tweet=\"$SEDG - SolarEdge to buy Italian e-mobility firm SMRE for $77M https://seekingalpha.com/news/3421123-solaredge-to-buy-italian-e-mobility-firm-smre-for-77m?source=tweet\" data-url=\"https://seekingalpha.com/news/3421123-solaredge-to-buy-italian-e-mobility-firm-smre-for-77m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421122\" data-ts=\"1546883473\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TBPH\" target=\"_blank\">TBPH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421122-theravance-up-4-on-downsizing-focus-on-late-stage-programs\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Theravance up 4% on downsizing, focus on late-stage programs</a></h4><ul><li>Theravance Biopharma (<a href='https://seekingalpha.com/symbol/TBPH' title='Theravance Biopharma, Inc.'>TBPH</a> <font color=\"green\">+3.7%</font>) is up on below-average volume on the heels of its <a href=\"https://seekingalpha.com/pr/17372396-theravance-biopharma-announces-alignment-workforce-focus-key-strategic-priorities\" target=\"_blank\">announced downsizing</a> aimed at sharpening its strategic focus on selected late-stage programs. The company plans to cut ~50 positions, mostly in early research and infrastructure support for VIBATIV (telavancin), recently sold to Cumberland Pharmaceuticals.</li><li>$JPM19</li></ul><div class=\"tiny-share-widget\" data-id=\"3421122\" data-linked=\"Theravance up 4% on downsizing, focus on late-stage programs\" data-tweet=\"$TBPH - Theravance up 4% on downsizing, focus on late-stage programs https://seekingalpha.com/news/3421122-theravance-up-4-on-downsizing-focus-on-late-stage-programs?source=tweet\" data-url=\"https://seekingalpha.com/news/3421122-theravance-up-4-on-downsizing-focus-on-late-stage-programs\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:51 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421119\" data-ts=\"1546883229\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AXSM\" target=\"_blank\">AXSM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421119-healthcare-dominate-midday-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare dominate midday movers</a></h4><ul><li><strong>Gainers:</strong> Axsome Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AXSM' title='Axsome Therapeutics'>AXSM</a>) <font color=\"green\">+217%</font>. Luxoft Holding (NYSE:<a href='https://seekingalpha.com/symbol/LXFT' title='Luxoft Holding Inc'>LXFT</a>) <font color=\"green\">+81%</font>. Loxo Oncology (NASDAQ:<a href='https://seekingalpha.com/symbol/LOXO' title='Loxo Oncology'>LOXO</a>) <font color=\"green\">+66%</font>. Sage Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SAGE' title='Sage Therapeutics'>SAGE</a>) <font color=\"green\">+44%</font>. QEP Resources (NYSE:<a href='https://seekingalpha.com/symbol/QEP' title='QEP Resources, Inc.'>QEP</a>) <font color=\"green\">+42%</font>. Insmed Incorporated (NASDAQ:<a href='https://seekingalpha.com/symbol/INSM' title='Insmed, Inc.'>INSM</a>) <font color=\"green\">+41%</font>. Centrus Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/LEU' title='Centrus Energy Corp.'>LEU</a>) <font color=\"green\">+41%</font>. Taiwan Liposome Company (<a href='https://seekingalpha.com/symbol/TLC' title='Taiwan Liposome Co.'>TLC</a>) <font color=\"green\">+32%</font>. Roku (NASDAQ:<a href='https://seekingalpha.com/symbol/ROKU' title='Roku Inc.'>ROKU</a>) <font color=\"green\">+26%</font>. CLPS Incorporation (NASDAQ:<a href='https://seekingalpha.com/symbol/CLPS' title='CLPS, Inc'>CLPS</a>) <font color=\"green\">+22%</font>.</li><li><strong>Losers: </strong>ContraFect Corporation (NASDAQ:<a href='https://seekingalpha.com/symbol/CFRX' title='ContraFect Corp.'>CFRX</a>) <font color=\"red\">-45%</font>. La Jolla Pharmaceutical (NASDAQ:<a href='https://seekingalpha.com/symbol/LJPC' title='La Jolla Pharmaceutical Co.'>LJPC</a>) <font color=\"red\">-43%</font>. PG&amp;E Corporation (NYSE:<a href='https://seekingalpha.com/symbol/PCG' title='PG&E Corporation'>PCG</a>) <font color=\"red\">-22%</font>. Natural Health Trends (NASDAQ:<a href='https://seekingalpha.com/symbol/NHTC' title='Natural Health Trends Corp.'>NHTC</a>) <font color=\"red\">-21%</font>. AxoGen (NASDAQ:<a href='https://seekingalpha.com/symbol/AXGN' title='AxoGen, Inc.'>AXGN</a>) <font color=\"red\">-21%</font>. Collegium Pharmaceutical (NASDAQ:<a href='https://seekingalpha.com/symbol/COLL' title='Collegium Pharmaceutical'>COLL</a>) <font color=\"red\">-18%</font>. Maxar Technologies (NYSE:<a href='https://seekingalpha.com/symbol/MAXR' title='Maxar Technologies Inc'>MAXR</a>) <font color=\"red\">-16%</font>. Cutera (NASDAQ:<a href='https://seekingalpha.com/symbol/CUTR' title='Cutera, Inc.'>CUTR</a>) <font color=\"red\">-15%</font>. Hi-Crush Partners (NYSE:<a href='https://seekingalpha.com/symbol/HCLP' title='Hi-Crush Partners LP'>HCLP</a>) <font color=\"red\">-15%</font>. NovaBay Pharmaceuticals (NYSEMKT:<a href='https://seekingalpha.com/symbol/NBY' title='NovaBay Pharmaceuticals, Inc.'>NBY</a>) <font color=\"red\">-13%</font>.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3421119\" data-linked=\"Healthcare dominate midday movers\" data-tweet=\"$AXSM $AXSM $LXFT - Healthcare dominate midday movers https://seekingalpha.com/news/3421119-healthcare-dominate-midday-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3421119-healthcare-dominate-midday-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421115\" data-ts=\"1546882774\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BHC\" target=\"_blank\">BHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421115-bausch-health-up-5-on-2019-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bausch Health up 5% on 2019 outlook</a></h4><ul><li>Bausch Health Companies (<a href='https://seekingalpha.com/symbol/BHC' title='Bausch Health Companies Inc.'>BHC</a> <font color=\"green\">+5.3%</font>) is up on average volume in response to its corporate <a href=\"https://ir.bauschhealth.com/~/media/Files/V/Valeant-IR/reports-and-presentations/20190107-jpmorgan.pdf\" target=\"_blank\">presentation </a>at JP Morgan's Healthcare Conference. Highlights:</li><li><strong>2019 outlook</strong>: total revenue should be up from 2018. Cash flow ops should be more than $1B and will be used to pay down debt and for possible \"bolt-on\" acquisitions. Sales from its \"significant seven\" products should double to ~$300M. CORE initiative should deliver more than $75M in operational efficiencies.</li><li>Four late-stage programs ongoing or planned in Salix unit (two for Rifaximin and two for Xifaxan).</li><li>Three-year CAGR of revenue expected to be 4 - 6% and 5 - 8% for non-GAAP EBITDA.</li><li>#JPM19</li></ul><div class=\"tiny-share-widget\" data-id=\"3421115\" data-linked=\"Bausch Health up 5% on 2019 outlook\" data-tweet=\"$BHC - Bausch Health up 5% on 2019 outlook https://seekingalpha.com/news/3421115-bausch-health-up-5-on-2019-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3421115-bausch-health-up-5-on-2019-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>58&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421111\" data-ts=\"1546882184\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421111-ring-launches-smart-peephole-security-lights\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ring launches smart peephole, security lights</a></h4><ul><li>Amazon's (<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a> <font color=\"green\">+3.1%</font>) Ring <a href=\"https://www.theverge.com/2019/1/7/18169243/ring-smart-doorbell-door-peephole-lights-smoke-security-smarthome-price-ces-2019\" target=\"_blank\">announces</a> 13 new products today ahead of <a href=\"https://seekingalpha.com/search/?q=CES19&amp;tab=news\" target=\"_blank\">#CES19</a>.</li><li>Key products:</li><li>The <a href=\"https://www.businesswire.com/news/home/20190107005843/en/CES-2019-Ring-Reimagines-Home-Security-Launches\" target=\"_blank\">Ring Door View Cam</a> can now install directly into a door, replacing the peephole and sensing knocks. The battery-powered Door View fits into an existing peephole slot. The Alexa-supporting Cam will launch in the US later this year for $199 with a European launch coming later.</li><li>The <a href=\"https://seekingalpha.com/news/3420068-ring-launching-new-security-lights\" target=\"_blank\">security lights</a> previewed in FCC filings are a reality with the wired Ring Floodlight costing $69.99 and the Ring Floodlight Battery costing $49.99.</li><li>The new Ring Transformer brings smart lighting capabilities to older models of landscape lighting and carries a $99.99 price tag.</li><li>Security products: The Smoke &amp; CO Listener ($35), First Alert Z-Wave Smoke / CO Alarm ($40), and Flood &amp; Freeze Sensor ($35) can detect threats and notify you through the Ring app. The Dome Siren will ring/flash to indicate security issues while you're home.</li><li>Ring Smart Lighting is available for preorder and will start shipping on March 6. The security products are available to purchase now.</li></ul><div class=\"tiny-share-widget\" data-id=\"3421111\" data-linked=\"Ring launches smart peephole, security lights\" data-tweet=\"$AMZN - Ring launches smart peephole, security lights https://seekingalpha.com/news/3421111-ring-launches-smart-peephole-security-lights?source=tweet\" data-url=\"https://seekingalpha.com/news/3421111-ring-launches-smart-peephole-security-lights\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421110\" data-ts=\"1546881736\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BMRN\" target=\"_blank\">BMRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421110-biomarin-up-4-on-2019-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BioMarin up 4% on 2019 outlook</a></h4><ul><li>BioMarin Pharmaceutical (<a href='https://seekingalpha.com/symbol/BMRN' title='BioMarin Pharmaceutical Inc.'>BMRN</a> <font color=\"green\">+4.3%</font>) is up on below-average volume on the heels of its <a href=\"https://seekingalpha.com/pr/17372323-biomarin-highlights-key-milestones-2019-37th-annual-j-p-morgan-healthcare-conference-san\" target=\"_blank\">announcement </a>of key milestones for this year. Highlights:</li><li>Decision on whether to submit U.S. marketing application for Orphan Drug- and Breakthrough Therapy-tagged valoctocogene roxaparvovec in hemophilia A via an accelerated pathway to be made in H2. Enrollment in a Phase 3 study should hit 130 by mid-year.</li><li>Topline data from a Phase 3 study of Orphan Drug-tagged vosoritide in children with achondroplasia (type of dwarfism) expected by year-end.</li><li>Opinion from the EMA's advisory committee CHMP on Palynziq (pegvaliase) in PKU patients at least 16 years old expected this quarter. Global expected sales this year are $70M - 100M.</li><li>Gene therapy manufacturing site completed in Novato, CA. Capacity is ~4K doses per year.</li><li>#JPM19</li></ul><div class=\"tiny-share-widget\" data-id=\"3421110\" data-linked=\"BioMarin up 4% on 2019 outlook\" data-tweet=\"$BMRN - BioMarin up 4% on 2019 outlook https://seekingalpha.com/news/3421110-biomarin-up-4-on-2019-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3421110-biomarin-up-4-on-2019-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:22 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421109\" data-ts=\"1546881429\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTSO\" target=\"_blank\">CTSO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421109-cytosorbents-announces-preliminary-fy18-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CytoSorbents announces preliminary FY18 results</a></h4><ul><li>CytoSorbents (<a href='https://seekingalpha.com/symbol/CTSO' title='Cytosorbents Corp'>CTSO</a> <font color='green'>+8.1%</font>) <a href=\"https://seekingalpha.com/pr/17372062-cytosorbents-issues-stockholder-letter-preliminary-2018-financial-results\" target=\"_blank\">expects</a> $22.3M, with additional 2018 grant revenue expected upon finalization of invoicing vs. a consensus of $22.69M.</li><li>Full-year product sales in 2018 of ~$20.2M (+51% Y/Y) and record Q4 2018 product sales of ~$5.4M.</li><li>2018 blended gross product margins in excess of 72%.</li><li>More than 56,000 CytoSorb cumulative treatments delivered, up from 35,000 treatments a year ago.</li><li>Cash position of ~$22.3M (Dec. 31, 2018).</li><li><a href=\"https://seekingalpha.com/cloudsearch/search?q=JPM19&amp;tab=news&amp;ticker=#1\" target=\"_blank\">#JPM19</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3421109\" data-linked=\"CytoSorbents announces preliminary FY18 results\" data-tweet=\"$CTSO - CytoSorbents announces preliminary FY18 results https://seekingalpha.com/news/3421109-cytosorbents-announces-preliminary-fy18-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3421109-cytosorbents-announces-preliminary-fy18-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421099\" data-ts=\"1546880866\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AXGN\" target=\"_blank\">AXGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421099-axogen-down-21-on-preliminary-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AxoGen down 21% on preliminary Q4 results</a></h4><ul><li>AxoGen (<a href='https://seekingalpha.com/symbol/AXGN' title='AxoGen, Inc.'>AXGN</a> <font color=\"red\">-20.8%</font>) is down on more than triple normal volume after its <a href=\"https://seekingalpha.com/pr/17371978-axogen-inc-pre-announces-financial-operational-results\" target=\"_blank\">announcement </a>of preliminary Q4 2018 and full-year results.</li><li>Q4 revenue was at least $23.4M, up 38% yoy but potentially shy of $24.2M consensus. Full-year revenue was at least $83.9M, also potentially short of $84.6M consensus.</li><li>2019 outlook: revenue growth of at least 35%. Gross margin to remain above 80%.</li><li>#JPM19</li></ul><div class=\"tiny-share-widget\" data-id=\"3421099\" data-linked=\"AxoGen down 21% on preliminary Q4 results\" data-tweet=\"$AXGN - AxoGen down 21% on preliminary Q4 results https://seekingalpha.com/news/3421099-axogen-down-21-on-preliminary-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3421099-axogen-down-21-on-preliminary-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421106\" data-ts=\"1546880775\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VZ\" target=\"_blank\">VZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421106-verizon-taps-another-snap-exec-for-sales-role\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Verizon taps another Snap exec for sales role</a></h4><ul>   <li>Verizon (<a href=\"http://seekingalpha.com/symbol/VZ\" target=\"_blank\">VZ</a> <font color=\"green\">+0.9%</font>) has turned to another ex-Snap (<a href=\"http://seekingalpha.com/symbol/SNAP\" target=\"_blank\">SNAP</a> <font color=\"green\">+2.4%</font>) exec for a key sales role.</li>    <li>Verizon Media -- the Internet unit formerly known as Oath -- has recruited Elizabeth Herbst-Brady as its <a href=\"https://variety.com/2019/digital/exec-shuffle-people-news/verizon-media-poaches-snaps-elizabeth-herbst-brady-as-head-of-u-s-field-sales-1203101304/\" target=\"_blank\">head of U.S. field sales</a>.</li>    <li>She'll report directly to Jeff Lucas, head of North American sales and global client solutions; Lucas left a role as Snap's global head of sales before joining Verizon.</li>    <li>At Snap, Herbst-Brady had managed major agency and brand relationships. She had previously served in key roles at Viacom and Magna Global.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3421106\" data-linked=\"Verizon taps another Snap exec for sales role\" data-tweet=\"$VZ $VZ $SNAP - Verizon taps another Snap exec for sales role https://seekingalpha.com/news/3421106-verizon-taps-another-snap-exec-for-sales-role?source=tweet\" data-url=\"https://seekingalpha.com/news/3421106-verizon-taps-another-snap-exec-for-sales-role\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421104\" data-ts=\"1546880481\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SOLO\" target=\"_blank\">SOLO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421104-westport-fuel-systems-and-mattel-among-consumer-gainers-natural-health-trends-leads-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Westport Fuel Systems and Mattel among consumer gainers; Natural Health Trends leads losers</a></h4><ul><li><b>Gainers: </b>Electrameccanica Vehicles (NASDAQ:<a href='https://seekingalpha.com/symbol/SOLO' title='Electrameccanica Vehicles Corp. Ltd.'>SOLO</a>) <font color=\"green\">+14%</font>. Westport Fuel Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/WPRT' title='Westport Fuel Systems, Inc.'>WPRT</a>) <font color=\"green\">+11%</font>. Planet Green Holdings (NYSEMKT:<a href='https://seekingalpha.com/symbol/PLAG' title='Planet Green Holdings Corp'>PLAG</a>) <font color=\"green\">+10%</font>. Mattel (NASDAQ:<a href='https://seekingalpha.com/symbol/MAT' title='Mattel, Inc.'>MAT</a>) <font color=\"green\">+10%</font>. Energous (NASDAQ:<a href='https://seekingalpha.com/symbol/WATT' title='Energous Corp.'>WATT</a>) <font color=\"green\">+9%</font>.</li><li><b>Losers: </b>Natural Health Trends (NASDAQ:<a href='https://seekingalpha.com/symbol/NHTC' title='Natural Health Trends Corp.'>NHTC</a>) <font color=\"red\">-20%</font>. Lamb Weston Holdings (NYSE:<a href='https://seekingalpha.com/symbol/LW' title='Lamb Weston Holdings, Inc.'>LW</a>) <font color=\"red\">-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3421104\" data-linked=\"Westport Fuel Systems and Mattel among consumer gainers; Natural Health Trends leads losers\" data-tweet=\"$SOLO $SOLO $WPRT - Westport Fuel Systems and Mattel among consumer gainers; Natural Health Trends leads losers https://seekingalpha.com/news/3421104-westport-fuel-systems-and-mattel-among-consumer-gainers-natural-health-trends-leads-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3421104-westport-fuel-systems-and-mattel-among-consumer-gainers-natural-health-trends-leads-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421105\" data-ts=\"1546880475\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IPG\" target=\"_blank\">IPG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421105-interpublic-groupplus-2_8-pivotal-raises-to-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Interpublic Group +2.8% as Pivotal raises to Buy</a></h4><ul>   <li>Interpublic Group (NYSE:<a href='https://seekingalpha.com/symbol/IPG' title='Interpublic Group of Companies Inc.'>IPG</a>) is <font color=\"green\">up 2.8%</font> after a boost to Buy at Pivotal.</li>    <li>Analyst Brian Wieser previously had a Hold recommendation on the advertising giant.</li>    <li>The company presents at Citi's TMT West Conference, held tomorrow and Wednesday in Las Vegas.</li>    <li><a href='https://seekingalpha.com/symbol/IPG' title='Interpublic Group of Companies Inc.'>IPG</a> is <font color=\"green\">up 4.9%</font> over the past year but has <font color=\"red\">slipped 12.7%</font> in the past month.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3421105\" data-linked=\"Interpublic Group +2.8% as Pivotal raises to Buy\" data-tweet=\"$IPG - Interpublic Group +2.8% as Pivotal raises to Buy https://seekingalpha.com/news/3421105-interpublic-groupplus-2_8-pivotal-raises-to-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3421105-interpublic-groupplus-2_8-pivotal-raises-to-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421101\" data-ts=\"1546880056\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RDC\" target=\"_blank\">RDC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421101-rowan-shareholder-canyon-capital-to-vote-against-ensco-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rowan shareholder Canyon Capital to vote against Ensco deal</a></h4><ul><li>Rowan (<a href='https://seekingalpha.com/symbol/RDC' title='Rowan Companies plc'>RDC</a> <font color='green'>+7.2%</font>) shareholder Canyon Capital says it <a href=\"https://seekingalpha.com/pr/17371508-canyon-partners-sends-letter-rowan-companies-plc-board-directors\" target=\"_blank\">plans to vote against</a> the company's proposed merger with Ensco (<a href='https://seekingalpha.com/symbol/ESV' title='Ensco PLC'>ESV</a> <font color='green'>+6.3%</font>), saying the all-stock deal <a href=\"https://www.bloomberg.com/news/articles/2019-01-07/canyon-capital-plans-to-vote-against-rowan-s-merger-with-ensco\" target=\"_blank\">undervalues RDC</a> and exposes the company's shareholders to operational and financial risks.</li><li>RDC investors would be better served if the company ran a competitive process that resulted in a sale at a higher price or a breakup and sale in parts, according to Canyon, which owns a 6.3% stake in the company.</li><li>Canyon says RDC has better assets  and a stronger balance sheet than the purchase price reflects, and believes the merger would saddle the company with ESV's older fleet of drilling rigs  as well as its $5.2B in long-term debt.</li><li>RDC stands by the deal, which the company says \"will create a uniquely positioned offshore drilling company with capabilities  across all water depths, a significant fleet size, a broad geographic  presence and a diverse customer base.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3421101\" data-linked=\"Rowan shareholder Canyon Capital to vote against Ensco deal\" data-tweet=\"$RDC $RDC $VAL - Rowan shareholder Canyon Capital to vote against Ensco deal https://seekingalpha.com/news/3421101-rowan-shareholder-canyon-capital-to-vote-against-ensco-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3421101-rowan-shareholder-canyon-capital-to-vote-against-ensco-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>71&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421097\" data-ts=\"1546879105\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FB\" target=\"_blank\">FB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421097-baird-stays-positive-on-facebook-dramas-subside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Baird stays positive on Facebook as dramas subside</a></h4><ul>   <li>Baird is reiterating its Outperform rating on Facebook (<a href=\"http://seekingalpha.com/symbol/FB\" target=\"_blank\">FB</a> <font color=\"red\">-0.5%</font>), saying engagement is starting to stabilize after a year of controversies.</li>    <li>It's basing its take on partner checks as well as an internal survey of users.</li>    <li>\"While we were more cautious through 2018, we are incrementally positive as trust and usage likely stabilize/improve this year,\" writes analyst Colin Sebastian. \"Instagram engagement growth is now on par with Facebook among younger cohorts (at Snapchat\u2019s (<a href=\"http://seekingalpha.com/symbol/SNAP\" target=\"_blank\">SNAP</a> <font color=\"green\">+2%</font>) expense), a positive given Instagram\u2019s contributions to revenue growth.\" (h/t Bloomberg)</li>    <li>Baird has a $195 price target, currently implying 42% upside.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3421097\" data-linked=\"Baird stays positive on Facebook as dramas subside\" data-tweet=\"$FB $FB $SNAP - Baird stays positive on Facebook as dramas subside https://seekingalpha.com/news/3421097-baird-stays-positive-on-facebook-dramas-subside?source=tweet\" data-url=\"https://seekingalpha.com/news/3421097-baird-stays-positive-on-facebook-dramas-subside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421096\" data-ts=\"1546878985\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SRPT\" target=\"_blank\">SRPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421096-sarepta-down-5-on-preliminary-exondys-51-sales\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sarepta down 5% on preliminary Exondys 51 sales</a></h4><ul><li>Sarepta Therapeutics (<a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a> <font color=\"red\">-4.8%</font>) is down on double normal in apparent response to its <a href=\"https://www.sec.gov/Archives/edgar/data/873303/000119312519003383/d687475d8k.htm\" target=\"_blank\">preliminary sales figures</a> for DMD med EXONDYS 51 (eteplirsen).</li><li>Q4 sales were ~$84.4M, below consensus of $85.8M. Full-year sales were ~$301M, in line with expectations.</li><li>Current consensus view for 2019 is $418.6M.</li><li>#JPM19</li></ul><div class=\"tiny-share-widget\" data-id=\"3421096\" data-linked=\"Sarepta down 5% on preliminary Exondys 51 sales\" data-tweet=\"$SRPT - Sarepta down 5% on preliminary Exondys 51 sales https://seekingalpha.com/news/3421096-sarepta-down-5-on-preliminary-exondys-51-sales?source=tweet\" data-url=\"https://seekingalpha.com/news/3421096-sarepta-down-5-on-preliminary-exondys-51-sales\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421094\" data-ts=\"1546878794\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ON\" target=\"_blank\">ON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421094-on-semi-3m-collab-on-self-driving-navigation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ON Semi, 3M collab on self-driving navigation</a></h4><ul><li>ON Semiconductor (<a href='https://seekingalpha.com/symbol/ON' title='ON Semiconductor Corporation'>ON</a> <font color='green'>+2.4%</font>) and 3M (<a href='https://seekingalpha.com/symbol/MMM' title='3M Company'>MMM</a> <font color='red'>-0.1%</font>) <a href=\"https://seekingalpha.com/pr/17372234-semiconductor-3m-collaborate-improve-roadway-safety\" target=\"_blank\">announce</a> a collaboration combining image sensing tech and roadway safety experience to improve self-driving vehicle navigation.</li><li>The companies will display ON's AR0234AT CMOS image sensor integrated into 3M's Smart Code sign technology during CES, which kicks off tomorrow.</li><li><a href=\"https://seekingalpha.com/search/?q=CES19&amp;tab=news\" target=\"_blank\">#CES19</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3421094\" data-linked=\"ON Semi, 3M collab on self-driving navigation\" data-tweet=\"$ON $ON $MMM - ON Semi, 3M collab on self-driving navigation https://seekingalpha.com/news/3421094-on-semi-3m-collab-on-self-driving-navigation?source=tweet\" data-url=\"https://seekingalpha.com/news/3421094-on-semi-3m-collab-on-self-driving-navigation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:33 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421090\" data-ts=\"1546878458\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CFRX\" target=\"_blank\">CFRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421090-contrafect-down-37-on-mid-stage-exebacase-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ContraFect down 37% on mid-stage exebacase data</a></h4><ul><li>Thinly traded nano cap ContraFect (<a href='https://seekingalpha.com/symbol/CFRX' title='ContraFect Corp.'>CFRX</a> <font color=\"red\">-36.6%</font>) is down on almost a 5x surge in volume following its <a href=\"https://seekingalpha.com/pr/17371410-contrafect-s-exebacase-cfminus-301-improved-clinical-outcomes-staphylococcus-aureus\" target=\"_blank\">announcement </a>of Phase 2 data on exebacase (CF-301) for the treatment <em>Staphylococcus aureus (S. aureus)</em> bacteremia including endocarditis.</li><li>Treatment with exebacase, a recombinant form of an enzyme called lysin, added to standard-of-care antibiotics resulted in a clinically meaningful improvement in response rate at day 14 compared to antibiotics alone, but the separation appeared to fall short of statistical significance. Specifically, the response rate in the exebacase cohort was 70.4% versus 60.0% for antibiotics alone.</li><li>The company says exebacase produced statistically significant treatment effects in methicillin-resistant <em>S. aureus</em> patients and in those with bacteremia alone.</li><li>On the safety front, the rate of treatment-emergent adverse events (TEAEs) was 88.9% for exebacase compared to 85.1% for antibiotics alone. The rates of serious TEAEs were 47.2% and 51.1%, respectively.</li><li>Exebacase acts by targeting a certain area of the cell wall that is essential to the bacterium, making it less likely to develop resistance.</li><li>A Phase 3 trial is next up.</li></ul><div class=\"tiny-share-widget\" data-id=\"3421090\" data-linked=\"ContraFect down 37% on mid-stage exebacase data\" data-tweet=\"$CFRX - ContraFect down 37% on mid-stage exebacase data https://seekingalpha.com/news/3421090-contrafect-down-37-on-mid-stage-exebacase-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3421090-contrafect-down-37-on-mid-stage-exebacase-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>72&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421089\" data-ts=\"1546878241\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KEYS\" target=\"_blank\">KEYS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421089-keysight-extends-cict-collab-keysplus-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Keysight extends CICT collab; KEYS +2%</a></h4><ul><li>Keysight Technologies (NYSE:<a href='https://seekingalpha.com/symbol/KEYS' title='Keysight Technologies Inc.'>KEYS</a>) <a href=\"https://seekingalpha.com/pr/17372244-keysight-technologies-cict-strengthen-commitment-collaborate-5g-technology-new-purchase\" target=\"_blank\">extends</a> its collaboration with China Information and Communication Technology Group with a new purchasing framework agreement.</li><li>The agreement includes KEYS' 5G test solutions, including channel emulators, signal generators, and signal analyzers.</li><li>Keysight shares are<font color=\"green\"> up 2.3%</font> to $63.39.</li></ul><div class=\"tiny-share-widget\" data-id=\"3421089\" data-linked=\"Keysight extends CICT collab; KEYS +2%\" data-tweet=\"$KEYS - Keysight extends CICT collab; KEYS +2% https://seekingalpha.com/news/3421089-keysight-extends-cict-collab-keysplus-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3421089-keysight-extends-cict-collab-keysplus-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421088\" data-ts=\"1546878192\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DDS\" target=\"_blank\">DDS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421088-dillards-rallies-after-jpmorgan-lift\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dillard&#39;s rallies after JPMorgan lift</a></h4><ul> <li>Shares of Dillard's (<a href='https://seekingalpha.com/symbol/DDS' title='Dillard&#39;s Inc.'>DDS</a> <font color='green'>+6.6%</font>) are on the move after JPMorgan <a href=\"https://www.marketwatch.com/story/dillards-shares-jump-6-after-jp-morgan-upgrade-on-upscale-shift-2019-01-07?link=MW_latest_news\" target=\"_blank\">upgrades</a> the department store operator to a Neutral rating from Underperform.</li> <li>The firm expects gross margin improvement out of Dillard's as the chain becomes more important to vendors amid retail store closings.</li> <li>JP's price target on Dillard's is pushed up to $62.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3421088\" data-linked=\"Dillard&#39;s rallies after JPMorgan lift\" data-tweet=\"$DDS - Dillard&#39;s rallies after JPMorgan lift https://seekingalpha.com/news/3421088-dillards-rallies-after-jpmorgan-lift?source=tweet\" data-url=\"https://seekingalpha.com/news/3421088-dillards-rallies-after-jpmorgan-lift\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:23 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421086\" data-ts=\"1546877822\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FWONA\" target=\"_blank\">FWONA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421086-deutsche-bank-significantly-boosts-valuation-of-universal-music\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Deutsche Bank significantly boosts valuation of Universal Music</a></h4><ul>   <li>Deutsche Bank has significantly raised its valuation of Vivendi's (<a href=\"http://seekingalpha.com/symbol/VIVHY\" target=\"_blank\">VIVHY</a> <font color=\"green\">+1.7%</font>) Universal Music Group, to \u20ac29B from a previous \u20ac20B.</li>    <li>That's notable since it's higher than the market capitalization of the parent company -- currently at \u20ac28.3B.</li>    <li>\"With the hype around UMG stake sale having subsided, there is now scope for valuation to surprise to the upside in 2H 2019,\" Deutsche Bank says. The bank sees music streaming revenue growing to $21B in 2023 from $7B last year in trade dollars; it has the aggregate market growing to $25B in that same span.</li>    <li>It also sees a number of potential partners in a UMG stake sale, notably Liberty Media (NASDAQ:<a href='https://seekingalpha.com/symbol/FWONA' title='Liberty Media Corp'>FWONA</a>), which controls Sirius XM (NASDAQ:<a href='https://seekingalpha.com/symbol/SIRI' title='Sirius XM Holdings Inc.'>SIRI</a>); Tencent Music (NYSE:<a href='https://seekingalpha.com/symbol/TME' title='Tencent Music Entertainment Group'>TME</a>) or Tencent (<a href='https://seekingalpha.com/symbol/TCEHY' title='Tencent Holding Ltd. ADR'>OTCPK:TCEHY</a>), the latter of which has more cash to deploy for such a deal; and others including Alphabet, Facebook, Amazon, Spotify, Apple or Alibaba.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3421086\" data-linked=\"Deutsche Bank significantly boosts valuation of Universal Music\" data-tweet=\"$FWONA $FWONA $SIRI - Deutsche Bank significantly boosts valuation of Universal Music https://seekingalpha.com/news/3421086-deutsche-bank-significantly-boosts-valuation-of-universal-music?source=tweet\" data-url=\"https://seekingalpha.com/news/3421086-deutsche-bank-significantly-boosts-valuation-of-universal-music\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421084\" data-ts=\"1546877306\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INN\" target=\"_blank\">INN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421084-summit-hotel-propertiesminus-3_0-after-downgrade-bofaml\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Summit Hotel Properties -3.0% after downgrade by BofAML</a></h4><ul><li>Summit Hotel Properties (NYSE:<a href='https://seekingalpha.com/symbol/INN' title='Summit Hotel Properties, Inc.'>INN</a>) <font color=\"red\">slumps 3.0% </font>after Bank of America Merrill Lynch analyst Shaun Kelley cuts his rating on the stock to underperform.</li><li>Lodging fundamentals \"suggest we are late cycle,\" as the buoyancy of the U.S. election and tax reform during 2017-'18 are replaced by \"pessimism around slowing growth, rising rates, and trade fears.\"</li><li>Sees U.S. RevPAR growth of 1%-2% vs 2018's +2.8%.</li><li>Source: Bloomberg First Word.</li><li><a href=\"https://seekingalpha.com/symbol/INN/earnings/analyst_ratings\" target=\"_blank\">Analyst ratings</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3421084\" data-linked=\"Summit Hotel Properties -3.0% after downgrade by BofAML\" data-tweet=\"$INN - Summit Hotel Properties -3.0% after downgrade by BofAML https://seekingalpha.com/news/3421084-summit-hotel-propertiesminus-3_0-after-downgrade-bofaml?source=tweet\" data-url=\"https://seekingalpha.com/news/3421084-summit-hotel-propertiesminus-3_0-after-downgrade-bofaml\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421080\" data-ts=\"1546877076\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LJPC\" target=\"_blank\">LJPC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421080-la-jolla-pharma-down-37-on-soft-giapreza-sales\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">La Jolla Pharma down 37% on soft Giapreza sales</a></h4><ul><li>La Jolla Pharmaceuticals (<a href='https://seekingalpha.com/symbol/LJPC' title='La Jolla Pharmaceutical Co.'>LJPC</a> <font color=\"red\">-36.7%</font>) is down on almost triple normal volume following its <a href=\"https://seekingalpha.com/pr/17371993-la-jolla-pharmaceutical-company-highlights-recent-corporate-progress-key-objectives\" target=\"_blank\">announcement</a> preliminary 2018 results and 2019 outlook.</li><li>On a preliminary basis, Q4 2018 and full-year sales of GIAPREZA (angiotensin II) were ~$4.2M and ~$10.1M, respectively, compared to consensus views of $7.8M and $13.5M, respectively.</li><li><strong>2019 outlook</strong>: GIAPREZA sales of $24M - 28M compared to consensus of $78.6M.</li><li>EMA decision on European application expected in June.</li><li>IND for malaria candidate LJPC-0118 in Q4.</li><li>Topline data from Phase 2 study of LJPC-401 in hereditary hemochromatosis in H2.</li><li>Topline data from pivotal study of LJPC-401 in beta thalassemia expected in mid-2020.</li><li>Cash consumption should be $89M - 94M ($172M in cash and equivalents at year-end 2018).</li><li>#JPM19</li></ul><div class=\"tiny-share-widget\" data-id=\"3421080\" data-linked=\"La Jolla Pharma down 37% on soft Giapreza sales\" data-tweet=\"$LJPC - La Jolla Pharma down 37% on soft Giapreza sales https://seekingalpha.com/news/3421080-la-jolla-pharma-down-37-on-soft-giapreza-sales?source=tweet\" data-url=\"https://seekingalpha.com/news/3421080-la-jolla-pharma-down-37-on-soft-giapreza-sales\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421079\" data-ts=\"1546876950\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AXSM\" target=\"_blank\">AXSM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421079-axsome-therapeutics-leads-healthcare-gainers-la-jolla-pharmaceutical-and-contrafect-among\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Axsome Therapeutics leads healthcare gainers; La Jolla Pharmaceutical and ContraFect among losers</a></h4><ul><li><b>Gainers: </b>Axsome Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AXSM' title='Axsome Therapeutics'>AXSM</a>) <font color=\"green\">+173%</font>. Loxo Oncology (NASDAQ:<a href='https://seekingalpha.com/symbol/LOXO' title='Loxo Oncology'>LOXO</a>) <font color=\"green\">+66%</font>. Taiwan Liposome Company (<a href='https://seekingalpha.com/symbol/TLC' title='Taiwan Liposome Co.'>TLC</a>) <font color=\"green\">+47%</font>. Sage Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SAGE' title='Sage Therapeutics'>SAGE</a>) <font color=\"green\">+42%</font>. Insmed (NASDAQ:<a href='https://seekingalpha.com/symbol/INSM' title='Insmed, Inc.'>INSM</a>) <font color=\"green\">+38%</font>.</li><li><b>Losers: </b>ContraFect (NASDAQ:<a href='https://seekingalpha.com/symbol/CFRX' title='ContraFect Corp.'>CFRX</a>) <font color=\"red\">-38%</font>. La Jolla Pharmaceutical (NASDAQ:<a href='https://seekingalpha.com/symbol/LJPC' title='La Jolla Pharmaceutical Co.'>LJPC</a>) <font color=\"red\">-36%</font>. AxoGen (NASDAQ:<a href='https://seekingalpha.com/symbol/AXGN' title='AxoGen, Inc.'>AXGN</a>) <font color=\"red\">-19%</font>. Cutera (NASDAQ:<a href='https://seekingalpha.com/symbol/CUTR' title='Cutera, Inc.'>CUTR</a>) <font color=\"red\">-16%</font>. Collegium Pharmaceutical (NASDAQ:<a href='https://seekingalpha.com/symbol/COLL' title='Collegium Pharmaceutical'>COLL</a>) <font color=\"red\">-12%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3421079\" data-linked=\"Axsome Therapeutics leads healthcare gainers; La Jolla Pharmaceutical and ContraFect among losers\" data-tweet=\"$AXSM $AXSM $LOXO - Axsome Therapeutics leads healthcare gainers; La Jolla Pharmaceutical and ContraFect among losers https://seekingalpha.com/news/3421079-axsome-therapeutics-leads-healthcare-gainers-la-jolla-pharmaceutical-and-contrafect-among?source=tweet\" data-url=\"https://seekingalpha.com/news/3421079-axsome-therapeutics-leads-healthcare-gainers-la-jolla-pharmaceutical-and-contrafect-among\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421067\" data-ts=\"1546876015\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GE\" target=\"_blank\">GE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421067-analysts-skeptical-of-potential-ge-apollo-jet-leasing-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analysts skeptical of potential GE-Apollo jet leasing deal</a></h4><ul><li>General Electric (<a href='https://seekingalpha.com/symbol/GE' title='General Electric'>GE</a> <font color='green'>+2.6%</font>) gains in early trading following a report late Friday that Apollo Global is <a href=\"https://seekingalpha.com/news/3420800-report-apollo-considering-bid-ges-jet-leasing-business\" target=\"_blank\">considering a bid for the company's jet leasing unit</a>, but Wall Street <a href=\"https://www.bloomberg.com/news/articles/2019-01-07/ge-apollo-jet-deal-draws-analyst-skepticism-as-value-questioned\" target=\"_blank\">analysts are skeptical</a> of the actual size of a potential deal and its impact on GE's turnaround.</li><li>The jet leasing unit could be valued at as much as $40B, according to the report, but J.P. Morgan's Stephen Tusa says the unit could be worth closer to $30B and is unlikely to be the \"silver bullet\" that some investors might be  expecting.</li><li>\"We remain skeptical on the company\u2019s ability to harvest enough value out of its assets to reduce liabilities, both hard and soft,\" Tusa writes.</li><li>Barclays' Julian Mitchell says while such a deal could reduce some of the  existential risks faced by the company, a lasting impact on the equity  value would require more clarity on the liabilities at GE  Capital; \"otherwise, the 'narrative' will remain impaired - i.e. 'good news is  really bad news,' in that GE has to sell assets because of a looming  major cash claim at [GE] Capital.\"</li><li>Gordon Haskett's John Inch says \"while a potential GECAS transaction could be worth $40B, this  would only match the book value of GECAS reported assets of just over  $40B. Consequently, it is not clear what debt would be assigned  to this transaction and what proceeds would be realized.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3421067\" data-linked=\"Analysts skeptical of potential GE-Apollo jet leasing deal\" data-tweet=\"$GE - Analysts skeptical of potential GE-Apollo jet leasing deal https://seekingalpha.com/news/3421067-analysts-skeptical-of-potential-ge-apollo-jet-leasing-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3421067-analysts-skeptical-of-potential-ge-apollo-jet-leasing-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>47&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421065\" data-ts=\"1546875987\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LEN\" target=\"_blank\">LEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421065-homebuilders-rise-keybanc-sees-rally-on-dovish-fed\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Homebuilders rise as KeyBanc sees rally on &quot;dovish&quot; Fed</a></h4><ul><li>The iShares Dow Jones US Home Construction ETF (BATS:<a href='https://seekingalpha.com/symbol/ITB' title='iShares U.S. Home Construction ETF'>ITB</a>) rises after KeyBanc analyst Kenneth Zener writes that homebuilders and building products should gain due to a more optimistic macro sentiment, Bloomberg First Word reports.</li><li>He upgrades Lennar (<a href='https://seekingalpha.com/symbol/LEN' title='Lennar Corporation'>LEN</a> <font color='green'>+3.1%</font>), PulteGroup (<a href='https://seekingalpha.com/symbol/PHM' title='PulteGroup, Inc.'>PHM</a> <font color='green'>+3.8%</font>), Masco(<a href='https://seekingalpha.com/symbol/MAS' title='Masco Corporation'>MAS</a> <font color='green'>+2%</font>), and Gibraltar Industries (<a href='https://seekingalpha.com/symbol/ROCK' title='Gibraltar Industries, Inc.'>ROCK</a> <font color='green'>+3.7%</font>) to overweight from sector-weight.</li><li>Sees H1 similar to previous trading cycles when builders rose 28% over six months as Powell's dovish commentary and Fed monetary policy should improve sentiment.</li><li>\"Being early can be wrong, but Fed commentary now warrants action,\" he writes.</li><li>In the same vein, lower mortgage rates--their lowest in about eight months--may <a href=\"https://www.wsj.com/articles/falling-mortgage-rates-raise-hopes-for-battered-housing-market-11546862400?mod=e2tw\" target=\"_blank\">boost the housing market </a>after a rough patch, the <em>Wall Street Journal</em> reports.</li><li>\u201cI think there is latent demand on the sidelines given where rates are today,\u201d said Sam Khater, Freddie Mac\u2019s chief economist. \u201cThe problem is that volatility is the obstacle.\u201d</li><li>Previously: <a href=\"https://seekingalpha.com/news/3419594-homebuilders-stocks-ready-ring-year\" target=\"_blank\">Homebuilders stocks ready to ring out the year</a> (Dec. 28, 2018)</li></ul><div class=\"tiny-share-widget\" data-id=\"3421065\" data-linked=\"Homebuilders rise as KeyBanc sees rally on &quot;dovish&quot; Fed\" data-tweet=\"$LEN $ITB $LEN - Homebuilders rise as KeyBanc sees rally on &quot;dovish&quot; Fed https://seekingalpha.com/news/3421065-homebuilders-rise-keybanc-sees-rally-on-dovish-fed?source=tweet\" data-url=\"https://seekingalpha.com/news/3421065-homebuilders-rise-keybanc-sees-rally-on-dovish-fed\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:46 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421061\" data-ts=\"1546875589\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLVS\" target=\"_blank\">CLVS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421061-clovis-rubraca-generated-over-30m-in-q4-2018-sales\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Clovis&#39; Rubraca generated over $30M in Q4 2018 sales</a></h4><ul><li>On a preliminary basis, Clovis Oncology (<a href='https://seekingalpha.com/symbol/CLVS' title='Clovis Oncology'>CLVS</a> <font color=\"green\">+17.6%</font>) <a href=\"https://seekingalpha.com/pr/17371647-clovis-oncology-announces-product-revenues-fourth-quarter-full-year-2018\" target=\"_blank\">reports </a>Q4 2018 and full-year sales for Rubraca (rucaparib) of $30.3M - 30.8M and $95.3M - 95.8M, respectively.</li><li>Cash and equivalents at year-end was $518M - 521M.</li><li>CEO Patrick Mahaffy will be presenting at JP Morgan's Healthcare Conference tomorrow, January 8, at 7:30 pm ET.</li><li>Shares are up in reaction to Eli Lilly's announced acquisition of Loxo Oncology for $8B.</li><li>$JPM18</li></ul><div class=\"tiny-share-widget\" data-id=\"3421061\" data-linked=\"Clovis&#39; Rubraca generated over $30M in Q4 2018 sales\" data-tweet=\"$CLVS - Clovis&#39; Rubraca generated over $30M in Q4 2018 sales https://seekingalpha.com/news/3421061-clovis-rubraca-generated-over-30m-in-q4-2018-sales?source=tweet\" data-url=\"https://seekingalpha.com/news/3421061-clovis-rubraca-generated-over-30m-in-q4-2018-sales\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421060\" data-ts=\"1546875496\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VIA\" target=\"_blank\">VIA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421060-report-cbs-seeking-ceo-who-also-run-viacom\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Report: CBS seeking CEO who could also run Viacom</a></h4><ul>   <li>Another data point for those reading the ever-changing tea leaves on a potential re-merger of CBS (<a href=\"http://seekingalpha.com/symbol/CBS\" target=\"_blank\">CBS</a> <font color=\"green\">+0.8%</font>) and Viacom (<a href='https://seekingalpha.com/symbol/VIA' title='Viacom Inc.'>VIA</a> <font color=\"green\">+1.7%</font>, <a href='https://seekingalpha.com/symbol/VIAB' title='Viacom Inc.'>VIAB</a> <font color=\"green\">+2.7%</font>): CBS has been telling CEO candidates it wants <a href=\"https://nypost.com/2019/01/06/cbs-wants-moonves-heir-to-run-viacom-too-if-merger-happens/\" target=\"_blank\">someone who can run both companies</a>, the <i>New York Post</i> reports.</li>    <li>While National Amusements (which controls both companies) has agreed not to approach CBS about such a merger until 2021, nothing's stopping CBS from starting such talks.</li>    <li>And CBS plans to do so, with hopes of announcing a new CEO and merger and a deal by March or April, according to the report.</li>    <li>Former CEO Les Moonves was in the way of such a deal, the report says, and interim chief Joe Ianniello doesn't have the standing to lead the two companies.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3421060\" data-linked=\"Report: CBS seeking CEO who could also run Viacom\" data-tweet=\"$VIA $VIA $VIAB - Report: CBS seeking CEO who could also run Viacom https://seekingalpha.com/news/3421060-report-cbs-seeking-ceo-who-also-run-viacom?source=tweet\" data-url=\"https://seekingalpha.com/news/3421060-report-cbs-seeking-ceo-who-also-run-viacom\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421055\" data-ts=\"1546875057\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ICPT\" target=\"_blank\">ICPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421055-intercept-pharma-up-4-ahead-of-data-readout-on-oca-in-nash\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intercept Pharma up 4% ahead of data readout on OCA in NASH</a></h4><ul><li>Intercept Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ICPT' title='Intercept Pharmaceuticals'>ICPT</a> <font color=\"green\">+4.1%</font>) is up on below-average volume following its <a href=\"https://seekingalpha.com/pr/17371409-intercept-announces-nash-pbc-program-updates\" target=\"_blank\">update </a>on it NASH and primary biliary cholangitis &#40;PBC&#41; programs.</li><li>It expects to report topline data from its Phase 3 REGENERATE study of obeticholic acid &#40;OCA&#41; in NASH patients with advanced liver fibrosis later this quarter.</li><li>Enrollment in the Phase 3 REVERSE study of OCA in NASH patients with compensated cirrhosis should be completed this year.</li><li>It expects to launch a Phase 2 study evaluating PPAR agonist bezafibrate, combined with OCA, in PBC patients. It acquired the U.S. rights to bezafibrate from Aralez Pharmaceuticals. Its long-term plan is to seek regulatory approval for a fixed-dose combination regimen for PBC and other potential indications.</li><li>$JPM19</li></ul><div class=\"tiny-share-widget\" data-id=\"3421055\" data-linked=\"Intercept Pharma up 4% ahead of data readout on OCA in NASH\" data-tweet=\"$ICPT - Intercept Pharma up 4% ahead of data readout on OCA in NASH https://seekingalpha.com/news/3421055-intercept-pharma-up-4-ahead-of-data-readout-on-oca-in-nash?source=tweet\" data-url=\"https://seekingalpha.com/news/3421055-intercept-pharma-up-4-ahead-of-data-readout-on-oca-in-nash\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421054\" data-ts=\"1546874923\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NFLX\" target=\"_blank\">NFLX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421054-netflix-rallies-after-strong-golden-globes-haul\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Netflix rallies after strong Golden Globes haul</a></h4><ul> <li>Netflix (<a href='https://seekingalpha.com/symbol/NFLX' title='Netflix, Inc.'>NFLX</a> <font color='green'>+4.3%</font>) had another good night at an awards show last night by raking in five Golden Globes to lead all networks and streamers.</li> <li>The company's <i>The Kominsky Method</i> <a href=\"https://www.goldenglobes.com/winners-nominees/best-television-series-musical-or-comedy\" target=\"_blank\">nabbed</a> two awards, including one for best musical or comedy TV series.</li> <li>Shares of Netflix are <font color=\"green\">up 3.69%</font> in morning trading.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3421054\" data-linked=\"Netflix rallies after strong Golden Globes haul\" data-tweet=\"$NFLX - Netflix rallies after strong Golden Globes haul https://seekingalpha.com/news/3421054-netflix-rallies-after-strong-golden-globes-haul?source=tweet\" data-url=\"https://seekingalpha.com/news/3421054-netflix-rallies-after-strong-golden-globes-haul\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421043\" data-ts=\"1546874071\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AKTS\" target=\"_blank\">AKTS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421043-akoustis-annonces-filter-order\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Akoustis annonces filter order</a></h4><ul><li>Akoustis (NASDAQ:<a href='https://seekingalpha.com/symbol/AKTS' title='Akoustis Technologies, Inc.'>AKTS</a>) announces receiving a pre-production order for its 5.2 GHz XBAW filters from a leading Wi-Fi SoC company, marking the third order for the 5.2 GHz filters.</li><li>Financial terms weren't disclosed.</li><li>Akoustis shares are <font color=\"green\">up 2%</font> to $5.84.</li></ul><div class=\"tiny-share-widget\" data-id=\"3421043\" data-linked=\"Akoustis annonces filter order\" data-tweet=\"$AKTS - Akoustis annonces filter order https://seekingalpha.com/news/3421043-akoustis-annonces-filter-order?source=tweet\" data-url=\"https://seekingalpha.com/news/3421043-akoustis-annonces-filter-order\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:14 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421041\" data-ts=\"1546874029\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IONS\" target=\"_blank\">IONS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421041-biotechs-up-out-gate-on-lilly-loxo-tie-up-and-start-of-jpm19\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biotechs up out the gate on Lilly/Loxo tie-up and start of JPM19</a></h4><ul><li>Healthcare investors are enjoying a rousing start to the week after Eli Lilly announced its takeover of Loxo Oncology and the release of a multitude of preliminary 2018 results for presenters at JPMorgan's 2019 Healthcare Conference (JPM19). The SPDR S&amp;P Biotech ETF (<a href='https://seekingalpha.com/symbol/XBI' title='SPDR Biotech ETF'>XBI</a> <font color=\"green\">+4.8%</font>) is up on modestly higher volume.</li><li>Selected tickers: (<a href='https://seekingalpha.com/symbol/IONS' title='Ionis Pharmaceuticals, Inc.'>IONS</a> <font color=\"green\">+4.1%</font>)(<a href='https://seekingalpha.com/symbol/ALNY' title='Alnylam Pharmaceuticals, Inc.'>ALNY</a> <font color=\"green\">+8.4%</font>)(<a href='https://seekingalpha.com/symbol/EDIT' title='Editas Medicine'>EDIT</a> <font color=\"green\">+3.9%</font>)(<a href='https://seekingalpha.com/symbol/CRSP' title='CRISPR Therapeutics'>CRSP</a> <font color=\"green\">+6.9%</font>)(<a href='https://seekingalpha.com/symbol/FPRX' title='Five Prime Therapeutics, Inc.'>FPRX</a> <font color=\"green\">+2.8%</font>)(<a href='https://seekingalpha.com/symbol/NKTR' title='Nektar Therapeutics'>NKTR</a> <font color=\"green\">+5.5%</font>)(<a href='https://seekingalpha.com/symbol/SNSS' title='Sunesis Pharmaceuticals, Inc.'>SNSS</a> <font color=\"green\">+29.7%</font>)(<a href='https://seekingalpha.com/symbol/SCYX' title='SCYNEXIS, Inc.'>SCYX</a> <font color=\"green\">+28.5%</font>)(<a href='https://seekingalpha.com/symbol/SPHS' title='Sophiris Bio'>SPHS</a> <font color=\"green\">+9.7%</font>)(<a href='https://seekingalpha.com/symbol/RETA' title='Reata Pharmaceuticals'>RETA</a> <font color=\"green\">+11%</font>)(<a href='https://seekingalpha.com/symbol/PTLA' title='Portola Pharmaceuticals'>PTLA</a> <font color=\"green\">+6.7%</font>)(<a href='https://seekingalpha.com/symbol/PIRS' title='Pieris Pharmaceuticals, Inc.'>PIRS</a> <font color=\"green\">+6.9%</font>)(<a href='https://seekingalpha.com/symbol/PFNX' title='Pfenex'>PFNX</a> <font color=\"green\">+9.1%</font>)(<a href='https://seekingalpha.com/symbol/OPHT' title='Ophthotech Corporation'>OPHT</a> <font color=\"green\">+8.8%</font>)(<a href='https://seekingalpha.com/symbol/ONCS' title='OncoSec Medical Incorporated'>ONCS</a> <font color=\"green\">+10.4%</font>)(<a href='https://seekingalpha.com/symbol/NVAX' title='Novavax, Inc.'>NVAX</a> <font color=\"green\">+6.5%</font>)(<a href='https://seekingalpha.com/symbol/NK' title='NantKwest'>NK</a> <font color=\"green\">+6%</font>)(<a href='https://seekingalpha.com/symbol/NAVB' title='Navidea Biopharmaceuticals'>NAVB</a> <font color=\"green\">+8.7%</font>)(<a href='https://seekingalpha.com/symbol/MRUS' title='Merus'>MRUS</a> <font color=\"green\">+13.4%</font>)(<a href='https://seekingalpha.com/symbol/INSM' title='Insmed, Inc.'>INSM</a> <font color=\"green\">+33.6%</font>)(<a href='https://seekingalpha.com/symbol/GENE' title='GENETIC TECHNOLOGIES LTD'>GENE</a> <font color=\"green\">+8.7%</font>)(<a href='https://seekingalpha.com/symbol/EVOK' title='Evoke Pharma, Inc.'>EVOK</a> <font color=\"green\">+8%</font>)(<a href='https://seekingalpha.com/symbol/CNAT' title='Conatus Pharmaceuticals'>CNAT</a> <font color=\"green\">+9.9%</font>)(<a href='https://seekingalpha.com/symbol/CTIC' title='CTI BioPharma Corp.'>CTIC</a> <font color=\"green\">+12.4%</font>)(<a href='https://seekingalpha.com/symbol/AXON' title='Axovant Sciences'>AXON</a> <font color=\"green\">+11.1%</font>)(APRI <font color=\"green\">+8.7%</font>)(<a href='https://seekingalpha.com/symbol/AGEN' title='Agenus'>AGEN</a> <font color=\"green\">+11.1%</font>)(<a href='https://seekingalpha.com/symbol/ADMS' title='Adamas Pharmaceuticals, Inc.'>ADMS</a> <font color=\"green\">+11.9%</font>)</li><li>#JPM19</li></ul><div class=\"tiny-share-widget\" data-id=\"3421041\" data-linked=\"Biotechs up out the gate on Lilly/Loxo tie-up and start of JPM19\" data-tweet=\"$IONS $XBI $IONS - Biotechs up out the gate on Lilly/Loxo tie-up and start of JPM19 https://seekingalpha.com/news/3421041-biotechs-up-out-gate-on-lilly-loxo-tie-up-and-start-of-jpm19?source=tweet\" data-url=\"https://seekingalpha.com/news/3421041-biotechs-up-out-gate-on-lilly-loxo-tie-up-and-start-of-jpm19\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421038\" data-ts=\"1546873761\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NLSN\" target=\"_blank\">NLSN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421038-nielsen-adds-youtube-coverage\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NIelsen adds YouTube coverage</a></h4><ul><li>Nielsen's (<a href='https://seekingalpha.com/symbol/NLSN' title='Nielsen Holdings N.V.'>NLSN</a> <font color='green'>+1.5%</font>) Total Ad Ratings, which lets marketers rank ad performance across platforms will <a href=\"https://seekingalpha.com/pr/17371229-nielsen-launches-enhanced-cross-platform-campaign-measurement-across-tv-digital-ads\" target=\"_blank\">now include</a> YouTube data for the first time.</li><li>The Total Ad Ratings will include mobile audiences, inclusive of Google's platform.</li></ul><div class=\"tiny-share-widget\" data-id=\"3421038\" data-linked=\"NIelsen adds YouTube coverage\" data-tweet=\"$NLSN - NIelsen adds YouTube coverage https://seekingalpha.com/news/3421038-nielsen-adds-youtube-coverage?source=tweet\" data-url=\"https://seekingalpha.com/news/3421038-nielsen-adds-youtube-coverage\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:09 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421030\" data-ts=\"1546873348\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BPMC\" target=\"_blank\">BPMC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421030-lilly-takeout-of-loxo-stokes-buying-in-cancer-players\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lilly takeout of Loxo stokes buying in other cancer players</a></h4><ul><li>Buying has spiked in a number of companies developing targeted cancer therapies after Eli Lilly's $8B takeout of Loxo Oncology.</li><li>Selected tickers: Blueprint Medicines (<a href='https://seekingalpha.com/symbol/BPMC' title='Blueprint Medicines'>BPMC</a> <font color=\"green\">+15.7%</font>), Deciphera Pharmaceuticals (<a href='https://seekingalpha.com/symbol/DCTH' title='Delcath Systems, Inc.'>OTC:DCTH</a> <font color=\"green\">+5.2%</font>), Epizyme (<a href='https://seekingalpha.com/symbol/EPZM' title='Epizyme'>EPZM</a> <font color=\"green\">+17.8%</font>), Clovis Oncology (<a href='https://seekingalpha.com/symbol/CLVS' title='Clovis Oncology'>CLVS</a> <font color=\"green\">+13.5%</font>), Array BioPharma (<a href='https://seekingalpha.com/symbol/ARRY' title='Array BioPharma Inc.'>ARRY</a> <font color=\"green\">+13.3%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3421030\" data-linked=\"Lilly takeout of Loxo stokes buying in other cancer players\" data-tweet=\"$BPMC $BPMC $DCTH - Lilly takeout of Loxo stokes buying in other cancer players https://seekingalpha.com/news/3421030-lilly-takeout-of-loxo-stokes-buying-in-cancer-players?source=tweet\" data-url=\"https://seekingalpha.com/news/3421030-lilly-takeout-of-loxo-stokes-buying-in-cancer-players\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421026\" data-ts=\"1546873260\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVYA\" target=\"_blank\">AVYA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421026-avaya-equal-weight-five9-overweight-morgan-stanley\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Avaya Equal Weight, Five9 Overweight at Morgan Stanley</a></h4><ul>   <li>Avaya Holdings (NYSE:<a href='https://seekingalpha.com/symbol/AVYA' title='Avaya Holdings Corp.'>AVYA</a>) is <font color=\"red\">off 0.8%</font> after an initiation at Equal Weight by Morgan Stanley.</li>    <li>Analyst Meta Marshall has set an $18.50 price target, implying 21.3% upside.</li>    <li>Meanwhile, Five9 (NASDAQ:<a href='https://seekingalpha.com/symbol/FIVN' title='Five9, Inc.'>FIVN</a>) is <font color=\"green\">up 10.1%</font>; Marshall upgraded the stock to Overweight from Equal Weight and boosted her price target to $54 from $37. That implies 15.4% further upside after this morning's gains.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3421026\" data-linked=\"Avaya Equal Weight, Five9 Overweight at Morgan Stanley\" data-tweet=\"$AVYA $AVYA $FIVN - Avaya Equal Weight, Five9 Overweight at Morgan Stanley https://seekingalpha.com/news/3421026-avaya-equal-weight-five9-overweight-morgan-stanley?source=tweet\" data-url=\"https://seekingalpha.com/news/3421026-avaya-equal-weight-five9-overweight-morgan-stanley\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421024\" data-ts=\"1546873153\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NHTC\" target=\"_blank\">NHTC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421024-natural-health-trendsminus-24-after-cctv-airs-allegations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Natural Health Trends -24% after CCTV airs allegations</a></h4><ul> <li>Shares of Natural Health Trends (NASDAQ:<a href='https://seekingalpha.com/symbol/NHTC' title='Natural Health Trends Corp.'>NHTC</a>) are <font color=\"red\">down 24.4%</font> after allegations against the company were aired on China Central Television.</li> <li>The company says it <a href=\"https://seekingalpha.com/pr/17371086-natural-health-trends-rejects-false-allegations-reiterates-commitment-ethical-business\" target=\"_blank\">believes</a> short sellers arranged the TV spot.</li> <li>Company statement: \"We are confident that our operations in China are in compliance with all applicable regulations. We believe these inaccurate claims were made in an effort to damage our brand, business in China, reputation and shareholder value, and we are prepared to vigorously defend our Company.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3421024\" data-linked=\"Natural Health Trends -24% after CCTV airs allegations\" data-tweet=\"$NHTC - Natural Health Trends -24% after CCTV airs allegations https://seekingalpha.com/news/3421024-natural-health-trendsminus-24-after-cctv-airs-allegations?source=tweet\" data-url=\"https://seekingalpha.com/news/3421024-natural-health-trendsminus-24-after-cctv-airs-allegations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3421023\" data-ts=\"1546872958\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADMA\" target=\"_blank\">ADMA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3421023-adma-bio-up-7-on-submission-of-responses-to-bivigam-crl\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ADMA Bio up 7% on submission of responses to Bivigam CRL</a></h4><ul><li>ADMA Biologics (<a href='https://seekingalpha.com/symbol/ADMA' title='ADMA Biologics Inc'>ADMA</a> <font color=\"green\">+7.1%</font>) is up on below-average volume in following its <a href=\"https://seekingalpha.com/pr/17371426-adma-biologics-submits-response-provides-supplemental-information-fda-bivigam-complete\" target=\"_blank\">announcement </a>that it has submitted its responses to the CRL it received from the FDA in December 2018 in response to its marketing application seeking approval for BIVIGAM (intravenous immune globulin [human], 10%).</li><li>The CRL cited the need for additional chemistry, manufacturing and controls &#40;CMC&#41; data.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3418457-fda-rejects-adma-bios-bivigam-application-shares-42-percent-premarket\" target=\"_blank\">FDA rejects ADMA Bio's Bivigam application; shares down 42% premarket</a> (Dec. 20, 2018)</li></ul><div class=\"tiny-share-widget\" data-id=\"3421023\" data-linked=\"ADMA Bio up 7% on submission of responses to Bivigam CRL\" data-tweet=\"$ADMA - ADMA Bio up 7% on submission of responses to Bivigam CRL https://seekingalpha.com/news/3421023-adma-bio-up-7-on-submission-of-responses-to-bivigam-crl?source=tweet\" data-url=\"https://seekingalpha.com/news/3421023-adma-bio-up-7-on-submission-of-responses-to-bivigam-crl\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}